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1. INTRODUCTION 
1.1 APOPTOSIS 
For the maintenance of cellular homeostasis, an exact balance between cellular 
proliferation and cell death is of utmost importance. If mitosis would proceed without 
cell death, an 80 year old person would have 2 tons of bone marrow and lymph 
nodes and an intestinal tract 16 km long (Kerr et al. 1972).  
The term “apoptosis” was first coined in 1972 by Kerr et al. and originates from the 
Greek words apo = from and ptosis = falling, symbolizing leaves falling from trees or 
petals falling from flowers, a natural process of death. The apoptotic mode of cell 
death is an active and defined process that plays an important role in the 
development of multicellular organisms and in the regulation and maintenance of the 
cell populations in tissues under physiologic and pathologic conditions. The 
disappearance of a cell by apoptosis creates “hardly a ripple” whereas necrosis is 
capable of producing inflammation. Programmed cell death is encoded in the 
genome. Each cell possesses the necessary molecular machinery required to 
undergo apoptosis, and the process can be initiated by specific cell signaling events. 
Numerous studies in recent years have revealed that apoptosis is a constitutive 
suicide program expressed in most, if not all cells, and can be triggered by a variety 
of extrinsic and intrinsic signals. Because the decision to live or to die critically 
contributes to the regulation of the immune response, the apoptotic pathways are 
kept under tight control (Elmore 2007; Hotchkiss et al. 2009). 
1.1.1  Historical perspective 
In 1858, Virchow characterized the changes occurring in cells shortly after death as 
either necrosis, where “the mortified cell is left in its external form” or “necrobiosis or 
shrinkage necrosis, where the cell vanishes and can no longer be seen in its 
previous form” (Virchow R et al. 1859). The term “necrobiosis” was succeeded by the 
term “chromatolysis” 26 years later, when Flemming described the morphological 
changes taking place during regression of the epithelium in mammalian lymphoid 
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follicles. In this study, the first drawings were produced, which illustrated what we 
now recognize as apoptosis (Flemming 1885). The theory of cell death as a 
mechanism involved in development, maintenance of homeostasis, control of organ 
size, and elimination of dysfunctional cells evolved over the following decades. In the 
late 1960s, apoptosis research was greatly facilitated by the use of electron 
microscopy. Now, the morphological changes occurring in apoptosis could be 
studied in much greater detail (Kerr 1969; Kerr 1971).  
A scientific landmark in apoptosis research occurred in 1972, when Kerr and 
colleagues published a paper in which they coined the term “apoptosis” (derived 
from a Greek word for “dropping off”, as in falling leaves) and defined this 
phenomenon as a type of orderly, active process by which cells undergo a series of 
morphological changes, ultimately leading to recognition and engulfment by 
phagocytes. They provided evidence that this built-in death program was not only 
evident during development or during pathological conditions, but also in the normal 
mature organism, continuing throughout life. The authors defined an important role 
for apoptosis in homeostasis and suggested that deregulation of apoptosis could 
lead to pathological conditions such as cancer (Kerr et al. 1972). 
At the beginning of the following decade, the interest for apoptosis was greatly 
increased with the discovery that glucocorticoids induce apoptosis and 
endonuclease activation in lymphocytes (Wyllie 1980). A few years later, the 
activation of endonucleases in apoptosis was demonstrated by gel electrophoresis, 
providing the first clear biochemical evidence for apoptosis (Duke et al. 1983). An 
understanding of the apoptosis process at the genetic and molecular level was 
initiated in 1986, when Horvitz, a Nobel Prize laureate of 2002, and Ellis discovered 
a set of genes in the nematode C. elegans that were involved in apoptosis (Ellis et 
al. 1986). These genes were later found to have homologues in a vast number of 
organisms, including humans. Since then, the list of apoptosis-related genes has 
expanded. 
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1.1.2 Natural occurrence of apoptosis 
Apoptosis is a widespread phenomenon occurring throughout the animal kingdom 
and human being. It is becoming clear that many of the genes involved in apoptosis 
control in mammals also function in plants. Apoptosis is involved in plant gamete 
fertilization, embryogenesis and development (Yin et al. 2003). The process has 
been described as dynamic, well coordinated but complex and is important in both 
the development and maintenance of living organisms (Clarke et al. 1998). 
Apoptotic processes begin as early as fertilization and are involved in a wide range 
of critical processes involved in homeostasis and development. Examples include 
development of the nervous system, whereby more nerve cells are produced than 
required (Oppenheim et al. 2001). Apoptosis adjusts the number of neuron, glial and 
neuroprogenitor cells to the number of target cells and it has been estimated that 
between 30-50% of all developed neurons die during development (Osborne 2004). 
Apoptosis is also involved in neural tube formation which in the developing embryo 
forms the brain, spinal cord, spinal nerves and spinal column. 
Apoptosis also occurs during morphogenesis of various body structures including 
muscle, epithelial, intestinal, gonadal cells and the immune system (Hengartner et al. 
1994). In non-aquatic vertebrates including humans, apoptosis of the inter-digital 
webs in the early embryo is important in the formation of fingers and toes (Hurle et 
al. 1996). In amphibians regression of the tail and gills of the tadpole, occurs as a 
result of substantial apoptosis (Fox 1973). In animals, which undergo 
metamorphosis, larval tissues that are no longer required are eliminated by 
apoptosis whilst the adult body parts emerge (Dyche 1979). Development of the 
reproductive tract requires regression of the male (wolffian) or female (müllerian) 
duct systems to produce a male or female embryo, and is another example of 
apoptosis. 
Apoptosis is just as important to the organism during postnatal development into 
adulthood. It is a mechanism whereby cells, which have served their purpose or 
become nonfunctional, can be eliminated safely without causing harm to the host. 
Follicular atresia of the post-ovulatory follicle and involution of the mammary gland 
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post-weaning are two examples of normal tissue regression achieved by apoptosis 
(Elmore 2007). Regulation of the immune system also requires apoptosis (Hotchkiss 
et al. 2009). The separation of the digits during limb development is classical 
example of the effect of apoptosis during apoptosis. Defective lymphocytes, 
lymphocytes that threaten an autoimmune attack or those, which have performed 
their duties, can all be eliminated safely via apoptosis (Gercel-Taylor et al. 2002; 
Osborne 2004). 
Furthermore, apoptotic cell death helps to shape the future inner ear structure, which 
starts from incubation day 5 in the chick inner ear. In cardiac morphogenesis, cell 
death is essential in generating the overall four-chambered architecture of the heart. 
In rat skeletal muscle, cell death persists during the ﬁrst three postnatal weeks, 
suggesting an indispensable role for cell death in the development of skeletal muscle 
(Osborne 2004). 
1.1.3 Morphological features of apoptosis 
During the early process of apoptosis, cell shrinkage and pyknosis are visible by light 
microscopy (Kerr et al. 1972). With cell shrinkage, the cells are smaller in size, the 
cytoplasm is dense and the organelles are more tightly packed. Pyknosis is the 
result of chromatin condensation and this is the most characteristic morphological 
feature of apoptosis (Osborne 2004) (Figure 1). 
Extensive plasma membrane blebbing followed by karyorrhexis and separation of 
cell fragments into apoptotic bodies during a process called "budding." Apoptotic 
bodies consist of cytoplasm with tightly packed organelles with or without a nuclear 
fragment. The organelle integrity is still maintained and all of this is enclosed within 
an intact plasma membrane. These bodies are subsequently phagocytosed by 
macrophages, parenchymal cells, or neoplastic cells and degraded within 
phagolysosomes (Wyllie 1980; Ucker et al. 1992; Mills et al. 1998; Kawabata et al. 
1999). Macrophages that engulf and digest apoptotic cells are called "tingible body 
macrophages" and are frequently found within the reactive germinal centers of 
lymphoid follicles or occasionally within the thymic cortex. The tingible bodies are the 
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bits of nuclear debris from the apoptotic cells. There is essentially no inflammatory 
reaction associated with the process of apoptosis nor with the removal of apoptotic 
cells because: (1) apoptotic cells do not release their cellular constituents into the 
surrounding interstitial tissue; (2) they are quickly phagocytosed by surrounding cells 
thus likely preventing secondary necrosis; and, (3) the engulfing cells do not produce 
inflammatory cytokines (Savill et al. 2000; Kurosaka et al. 2003). 
1.1.4 Apoptosis versus necrosis 
The alternative to apoptotic cell death is necrosis, which is considered to be a toxic 
process, where the cell is a passive victim and follows an energy-independent mode 
of death. But since necrosis refers to the degradative processes that occur after cell 
death, it is considered by some to be an inappropriate term to describe a mechanism 
of cell death. Oncosis is therefore used to describe a process that leads to necrosis 
with karyolysis and cell swelling, whereas apoptosis leads to cell death with cell 
shrinkage, pyknosis, and karyorrhexis. Therefore the terms "oncotic cell death" and 
"oncotic necrosis" have been proposed as alternatives to describe cell death that is 
accompanied by cell swelling. However, these terms are not widely used at this time 
(Majno et al. 1995; Levin et al. 1999). 
Some of the major morphological changes that occur with necrosis include cell 
swelling, formation of cytoplasmic vacuoles, distended endoplasmic reticulum, 
formation of cytoplasmic blebs, condensed, swollen or ruptured mitochondria, 
disaggregation and detachment of ribosomes, disrupted organelle membranes, 
swollen and ruptured lysosomes, and eventually disruption of the cell membrane 
(Kerr et al. 1972; Majno et al. 1995; Trump et al. 1997). This loss of cell membrane 
integrity results in the release of the cytoplasmic contents into the surrounding tissue 
sending chemotactic signals with eventual recruitment of inflammatory cells. By 
contrast, apoptotic cells do not release their cellular constituents into the surrounding 
interstitial tissue and are quickly phagocytosed by macrophages or adjacent normal 
cells, there is essentially no inflammatory reaction (Savill et al. 2000; Kurosaka et al. 
2003) (Figure 1 and Table 1).  
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Figure 1. Hallmarks of the apoptotic and necrotic cell death process 
Apoptosis includes cellular shrinking, chromatin condensation and margination at the nuclear 
periphery with the eventual formation of membrane-bound apoptotic bodies that contain 
organelles, cytosol and nuclear fragments and are phagocytosed without triggering 
inflammatory processes. The necrotic cell swells, becomes leaky and finally is disrupted and 
releases its contents into the surrounding tissue resulting in inflammation. Modified from (Van 
Cruchten et al. 2002) 
Table 1. Comparison of morphological features of apoptosis and necrosis (Elmore 
2007) 
Apoptosis Necrosis 
Single cells or small clusters of cells 
Cell shrinkage and convolution 
Pyknosis and karyorrhexis 
Intact cell membrane 
Cytoplasm retained in apoptotic bodies 
No inflammation 
Often contiguous cells 
Cell swelling 
Karyolysis, pyknosis, and karyorrhexis 
Disrupted cell membrane 
Cytoplasm is released 
Inflammation is usually present 
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1.1.5 Biochemical features of apoptosis 
Apoptotic cells exhibit several biochemical modifications such as protein cleavage, 
protein cross-linking, DNA breakdown, and phagocytic recognition that together 
result in the distinctive structural pathology described previously (Hengartner et al. 
1994).  
Caspases belong to the family of cysteine proteases, which play essential roles in 
apoptosis and inflammation. They are expressed as inactive proenzyme forms in 
most cells and once activated, can often activate other procaspases, allowing the 
initiation of a protease cascade. Some procaspases can also aggregate and 
autoactivate. This proteolytic cascade, in which one caspase can activate other 
caspases, amplifies the apoptotic signaling pathway and, thus, leads to rapid cell 
death. 
DNA breakdown by Ca++ and Mg++ dependent endonucleases also occurs, resulting 
in DNA fragments of 180 to 200 base pairs (Bortner et al. 1995). A characteristic 
"DNA ladder" can be visualized by agarose gel electrophoresis with ethidium 
bromide staining and ultraviolet illumination. 
Another biochemical feature is the expression of cell surface markers that results in 
the early phagocytic recognition of apoptotic cells by adjacent cells, permitting quick 
phagocytosis with minimal compromise to the surrounding tissue. This is achieved by 
the movement of the normally inward-facing phosphatidylserine of the cell’s lipid 
bilayer to the outer layer of the plasma membrane resulting in the surface expression 
of phosphatidylserine (Bratton et al. 1997). 
1.1.6 Apoptosis pathways (induction of apoptosis) 
There are three alternative pathways, through which apoptosis can be initiated,       
1-Death receptor (extrinsic) pathway, 2- Mitochonderial (Intrinsic) pathway,              
3-Perforin/granzyme pathway (Figure 2). 
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Figure 2. Schematic representation of apoptosis pathways 
The two main pathways of apoptosis are extrinsic and intrinsic, as well as, a 
perforin/granzyme pathway. Each requires specific trigger signals to initiate an energy-
dependent cascade of molecular events. Each pathway activates its own initiator caspase (8, 
9, and 10) which, in turn, will activate the executioner caspase 3. However, granzyme A 
works in a caspase-independent fashion. The execution pathway results in characteristic 
cytomorphological features including cell shrinkage, chromatin condensation, formation of 
cytoplasmic blebs and apoptotic bodies and finally phagocytosis of the apoptotic bodies by 
adjacent parenchymal cells, neoplastic cells or macrophages (Elmore 2007). 
1.1.6.1 Extrinisic (death receptor) pathway 
The extrinsic pathway is mediated by the death receptor CD95 (APO-1/Fas). 
Triggering of CD95 by its natural ligand or agonistic antibodies induces the formation 
of DISC that consists of the adapter protein FADD and FLICE/caspase 8. Complex 
formation is initiated through homophilic interaction of the death domains present in 
the intracellular part of both CD95 and FADD. FADD, in addition, contains a second 
interaction region called the DED, which couples to caspase 8 as the most proximal 
element in the caspase cascade. Further downstream, caspase 8 presumably 
triggers the proteolytic activation of other caspases and cleavage of cellular 
substrates (Schulze-Osthoff et al. 1998; Krammer 1999)  
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1.1.6.2 Intrinsic (mitochondrial) pathway 
The mitochondrial pathway of apoptosis is activated by DNA damage, cell cycle 
deregulation, hypoxia, and growth factor withdrawal. Signals induced by these stimuli 
lead to permeabilization of the outer membrane of the mitochondria, promoting the 
release of cytochrome c. When cytochrome c is released, it associates with apoptotic 
protease activating factor 1 (Apaf-1), allowing for the recruitment of an inactive 
initiator caspase, procaspase 9. The resulting protein complex, the apoptosome, 
enables the activation of procaspase 9 into caspase 9. Caspase 9 then activates 
executioner caspases such as caspase 3 (Li et al. 1997; Stennicke et al. 1999).  
1.1.6.3 Perforin/granzyme pathway 
T-cell mediated cytotoxicity is a variant of type IV hypersensitivity, where sensitized 
CD8+ cells kill antigen-bearing cells. These cytotoxic T lymphocytes (CTLs) are able 
to kill target cells via the extrinsic pathway and the FasL/FasR interaction is the 
predominant method of CTL-induced apoptosis (Brunner et al. 2003). However, they 
are also able to exert their cytotoxic effects on tumor cells and virus-infected cells via 
a novel pathway that involves secretion of the transmembrane pore-forming molecule 
perforin with a subsequent exophytic release of cytoplasmic granules through the 
pore and into the target cell (Trapani et al. 2002). The serine proteases granzyme A 
and granzyme B are the most important component within the granules. 
Granzyme B will cleave proteins at aspartate residues and will therefore activate 
procaspase 10 and can cleave factors like ICAD (inhibitor of caspase activated 
DNAse) (Sakahira et al. 1998). Reports have also shown that granzyme B can utilize 
the mitochondrial pathway for amplification of the death signal by specific cleavage of 
Bid and induction of cytochrome c release (Barry et al. 2002; Russell et al. 2002). 
However, granzyme B can also directly activate caspase 3. In this way, the upstream 
signaling pathways are bypassed and there is direct induction of the execution phase 
of apoptosis. 
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1.2 Mammalian target of rapamycin (mTOR) signaling 
1.2.1 The mTOR proteins 
The TOR proteins are a family of serine/threonine protein kinases that include 
ataxia–telangiectasia mutated (ATM), Rad3-related (ATR), DNA-dependent protein 
kinase (DNA-PK), and suppressor of morphogenesis in genitalia-1 (SMG-1) protein 
kinase. These kinases are characterized by large size (>2,500 amino acid) and a C-
terminally located kinase domain (Abraham 2004). The C-terminal kinase domains 
are similar to the kinase domain of phosphoinositide-3-kinase (PI3K), and from here 
they get the name PI3K-related kinases (PIKKs). The N-terminus possesses 20 
tandem HEAT domains, which are named based on their presence in Huntingtin 
protein, Elongation factor 3, the A subunit of PP2A and TOR1. 
The mammalian target of rapamycin (mTOR) is an atypical serine/threonine protein 
kinase with a molecular weight of 290 kDa. Structurally, the N-terminus of mTOR 
consists of 20 tandemly repeated motifs (HEAT motifs).  
The C-terminus consists of mutated FRAP-ataxia-teleangiectasia (FAT, FRAP) 
domain, a transformation/transcription domain-associated protein domain, an 
FKPB12-rapamycin-binding (FRB) domain, a catalytic kinase domain, and a FAT 
carboxy-terminal domain (FAT C-terminus, FATC). It is speculated that the HEAT 
repeats serve to mediate protein-protein interactions, the FRB domain as suggested 
by its name provides a docking site for the FKBP12/rapamycin complex, and the 
FAT and FATC domains modulate mTOR kinase activity via unknown mechanisms 
(Yang et al. 2007) (Figure 3). 
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Figure 3. The primary structure of the mTOR protein 
Starting from the N terminus to the C terminus, mTOR protein consists of HEAT (huntingtin, 
EF3, A subunit of PP2A, TOR) repeat domains, FRAP-ataxia-teleangiectasia (FAT) domain. 
FRB domain (FKBP12-rapamycin binding), is a small protein domain able to bind FKBP12-
rapamycin complex. The C-terminal FATC domain has been proposed to interact with the 
FAT domain to yield a configuration that exposes the catalytic domain (after (Bai et al. 2009)). 
The mTOR pathway is a key regulator of cell growth and proliferation and increasing 
evidence suggests that its deregulation is associated with human diseases, including 
cancer and diabetes (Sarbassov et al. 2005). The mTOR signaling pathway is 
considered to be the central regulator of ribosome biogenesis, protein synthesis, and 
cell growth. 
mTOR is found in two structurally and functionally distinct complexes to regulate 
growth and metabolism. In mammals, the mTOR complex 1 (mTORC1) contains 
mTOR, mLST8 (G protein beta protein subunit-like, GβL), PRAS40 (a proline-rich 
Akt substrate of 40 kDa, a raptor-interacting protein), raptor (regulatory associated 
protein of mTOR), and deptor (mTOR-interacting protein, inhibitory protein). 
mTORC1 is sensitive to the immunosuppressive and anticancer drug rapamycin. 
mTORC2 contains mTOR, mLST8, rictor (rapamycin-insensitive companion of 
mTOR, also known as the mammalian homolog of AVO3P, mAVO3), mSIN1 
(mammalian stress-activated protein kinase interacting protein 1, MIP1, mAVO1, the 
mammalian homolog of Avo1p, necessary for mTORC2 assembly and Akt/PKB 
phosphorylation), PRR5 (proline-rich protein 5, belongs to the small family of 
pseudo-response regulators (PRRs)) and deptor. The mTORC2 complex is 
insensitive to rapamycin (Bai et al. 2009; Peterson et al. 2009) (Figure 4).  
The two complexes signal via different effectors pathways to control distinct cellular 
processes. The mTORC1 protein kinase complex is the central component of a 
pathway that promotes growth in response to insulin, energy levels, and amino acids 
and is deregulated in common cancers. The mTORC2 complex phosphorylates Akt 
at Serine 473 (Ser473) and regulates the actin cytoskeleton (Jacinto et al. 2004; 
Sarbassov et al. 2005; Sancak et al. 2008).  
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Figure 4. Schematic representation of the mTOR complex components 
The mTORC1 complex consists of mTOR, mLST8, PRAS40 and raptor and the mTORC2 
complex consists of mTOR, mLST8, rictor, mSIN1, and PRR5 (after (Bai et al. 2009; Peterson 
et al. 2009)). 
1.2.2 Regulation of mTOR Activity 
1.2.2.1 Activation of mTOR by the PI3K signaling pathway  
The phosphoinositide 3-kinase (PI3K) pathway has a critical role in aggressive 
tumorigenesis. PI3K signaling is activated by various extracellular signals including 
peptide growth factors such as insulin and insulin-like growth factors (IGFs). The 
PI3K activity that results in PIP3 production is tightly controlled and negatively 
regulated by several phosphatases. The PTEN (phosphatase and tensin homolog on 
chromosome 10) lipid phosphatase dephosphorylates PIP3 at the 3’ position, 
whereas SHIP-1 phosphatase dephosphorylates it at the 5’ position, in both cases 
limiting the production of PIP3. Genetic inactivation of PTEN, e.g. by mutation, leads 
to constitutive activation of the PI3K/AKT/TSC2/mTORC1 cascade (Hay et al. 2004). 
AKT is a serine/threonine kinase, also known as protein kinase B, a critical 
downstream effector of PI3K. Mammalian cells express three Akt proteins encoded 
by different genes. Full activation of AKT requires AKT phosphorylation at Ser473 
and Threonine (Thr308) by PI3K and PDK1 (the phosphoinositide-dependent protein 
kinase), respectively. AKT phosphorylates TSC2, destabilizes it and disrupts its 
interaction with TSC1 leading to activation of mTOR (Bai et al. 2009) (Figure 5, 
Figure 6). 
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1.2.2.2 Inhibition of mTOR by the LKB1/AMPK/TSC2 signaling pathway  
The serine/threonine kinase LKB1 is a tumor suppressor gene. LKB1 is a central 
regulator of cell polarity and energy metabolism through its capacity to activate 
adenine monophosphate-activated protein kinase (AMPK). AMPK is activated in 
response to ATP depletion or increased AMP levels. Activation of AMPK 
phosphorylates and activates TSC2 inducing mTOR downregulation (Bai et al. 2009; 
Meric-Bernstam et al. 2009) (Figure 5, Figure 6).  
 
Figure 5. The mammalian target of rapamycin (mTOR) signaling 
Arrows represent activation, bars represent inhibition. mTOR signaling regulates critical 
cellular processes (after (Meric-Bernstam et al. 2009)). 
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1.2.2.3 Inhibition of mTOR by the tuberous sclerosis complex (TSC1/TSC2)  
Tuberous Sclerosis Complex (TSC) is a genetic disorder that occurs upon mutation 
of either the TSC1 or TSC2 gene, which encodes Hamartin or Tuberin, respectively. 
The TSC1/TSC2 (TSC1/2) has been known as the major upstream inhibitory 
regulator of mTOR. TSC2 protein contains a GAP homology domain at its C-
terminus. In vitro, TSC2 stimulates GTP hydrolysis of Rheb. TSC1 does not have 
any GAP activity and is not required for TSC2 GAP activity towards Rheb in vitro. 
Rheb (Ras homolog enriched in brain) is a member of the Ras family proteins. Rheb, 
a small GTPase that belongs to a unique family within the Ras superfamily of 
GTPases. The small GTPase Rheb is a positive upstream regulator of the target of 
mTORC1. TSC2 regulates Rheb-GTP levels. TSC2 acts as a GTPase-activating 
protein (GAP) for Rheb. Therefore, TSC2 inhibits Rheb activity. Rheb in its active 
GTP-bound state (Rheb-GTP) binds to and activates mTORC1. TSC1/2 inhibits 
mTORC1 activity by limiting the amount of GTP-bound Rheb available to stimulate 
mTORC1 (Hay et al. 2004; Bai et al. 2009).  
Multiple signaling cascades converge on TSC2, leading to its phosphorylation and 
inactivation. TSC2 is phosphorylated by multiple kinases, including Akt, RSK1, ERK, 
and AMPK (Bai et al. 2009) (Figure 6).  
Active Akt phosphorylates TSC2 directly on multiple sites (Ser939, Ser981, and 
Thr1462). Phosphorylation of TSC2 inactivates the GTPase activator domain 
function of TSC2, disrupts the TSC1/2 complex and stimulates activity of Rheb and 
mTOR (Tee et al. 2003). 
 Under energy starvation conditions, the AMP-activated protein kinase (AMPK) 
phosphorylates TSC2 at Thr1227 or Ser1345. The phosphorylation of TSC2 at these 
sites by AMPK improves the ability of TSC2 to inhibit mTOR activity by activating 
GAP activity of TSC2 (Inoki et al. 2003). 
ERK, and RSK directly phosphorylate TSC2 at Ser664 and Ser1798 resulting in 
inhibition of TSC2 function (Bai et al. 2009). 
 
INTRODUCTION 
 
 
15 
 
 
 
Figure 6. Schematic representation of TSC2/TSC1 complex regulation. 
(after (Bai et al. 2009)). 
1.2.2.4 Regulation of pathways downstream of mTOR  
The downstream signals of mTOR are characterized by two independent targets, 
p70S6K and 4EBP1/eIF4E complex. 
1.2.2.5 Regulation of p70S6K activation 
The p70S6K is a major downstream effector of the mammalian target of rapamycin. 
The p70S6K is a mitogen-activated serine/threonine kinase, which plays a crucial 
role in the control of the cell cycle (during progression through the G1 phase), of 
growth and survival. The p70S6K phosphorylates the 40S ribosomal protein S6, 
leading to upregulation of translation and protein synthesis. The p70S6K is regulated 
by diverse extracellular signals. The activity of p70S6K is controlled by multiple 
phosphorylation events located within the catalytic, linker and pseudosubstrate 
domains. Activation of p70S6K depends on the level of its phosphorylation state at 
eight sites: Thr229, Ser371, Thr389, Ser404, Ser411, Ser418, Thr421, and Ser424. 
Phosphorylation of Thr229 in the catalytic domain and Thr389 in the linker domain 
are most critical for the kinase function. The mTORC1 complex phosphorylates 
p70S6K at Thr389 and Ser371. PDK1 binds to and phosphorylates p70S6K at 
Thr229 (Pearson et al. 1995; Pullen et al. 1997; Dufner et al. 1999). The carboxyl 
terminus of p70S6K has a set of Ser and Thr residues (Ser411, Ser418, Ser424, and 
Thr421), which might be phosphorylated by the MAP kinases ERK1/2 and p38 
(Mukhopadhyay et al. 1992).  
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1.2.2.6 Regulation of the 4E-BP1/eIF4E complex 
The 4E-BP1 is a downstream component of the mTOR pathway. 4E-BP1 is a protein 
identified as a repressor of the cap-binding protein (eIF4E). 4EBP1 binds to eIF4E, 
which prevents the formation of the active eIF4F complex (eIF4A-eIF4G-eIF4E 
complex). Hyperphosphorylation of 4EBP1 by mTOR results in the release of eIF4E, 
thus, allowing the translation complex to assemble (Hay et al. 2004). Downregulation 
of mTOR induces hypophosphorylation of 4E-BP1 leading to 4E-BP1 binding to 
eIF4E, and inhibition of cap-dependent translation. 
Eukaryotic translation initiation factor 4E (eIF4E), the mRNA 5'-cap-binding protein, 
is a central component in the initiation and regulation of translation in eukaryotic 
cells. EIF4E binds to the mRNA cap structure to mediate the initiation of translation. 
EIF4E is implicated as important regulator of translation, which plays a crucial role in 
the malignant transformation, progression, and chemoresistance of many cancers 
Elevated eIF4E levels correlate with poor prognosis in many cancers including 
prostate cancer (De Benedetti et al. 2004). The level of free eIF4E might be raised 
due to increased eIF4E expression or increased phosphorylation and expression of 
4EBP1 (De Benedetti et al. 2004).  
Mnk1 phosphorylates eIF4E on its physiological site Ser209 only when eIF4E binds 
to eIF4F complex (Ross et al. 2006). The relation between the phosphorylation of 
eIF4E and protein translation is controversial. Thus, it has been reported that 
phosphorylation of eIF4E has either stimulatory (Waskiewicz et al. 1999) or inhibitory 
(Knauf et al. 2001), or has no effect at all (Morley et al. 2002) on protein translation. 
In addition, biophysical studies elucidated that phosphorylation of eIE4E decreases 
its cap-binding affinity, increasing the rate of eIF4E-m7GTP cap complex dissociation 
(Scheper et al. 2002). However, this could depend on the cell type and the 
experimental condition used. This controversial situation somehow seem sto indicate 
that phosphorylation of eIF4E may not be necessary for the assembly of the eIF4E 
complex or the general protein translation. However, it has been clearly shown that 
inhibition of mTOR by rapamycin or other compounds in vitro and vivo increases the 
phosphorylation status of eIF4E (Tee et al. 2000; Sun et al. 2005; Wang et al. 2007; 
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Chen et al. 2009; Zhu et al. 2009). Combination of rapamycin and inhibitors against 
MnK, ERK, p38 MAPK or PI3K revealed that upregulation of eIF4E phosphorylation 
depends on PI3K signaling and is independent of the MnK signaling pathway (Sun et 
al. 2005). Knockdown of the MnK1 expression decreased the basal level of p-eIF4E 
but could not prevent its phosphorylation being increased by rapamycin. Knockdown 
of mTOR (mTOR siRNA) or raptor (raptor siRNA), yet not rictor (rictor siRNA) 
hindered the phosphorylation of eIF4E by rapamycin (Wang et al. 2007). This 
indicates that rapamycin induced eIF4E phosphorylation depends on the presence of 
mTOR. 
 
Figure 7. Mechanism of translation intiation  
Hypophosphorylated 4EBP1 sequesters EIF4E. Hyperphosphorylation of 4EBP1 results in 
the dissociation of 4EBP1 from eIF4E and the subsequent association of eIF4E with eIF4G. 
EIF4G functions as a scaffolding protein that assembles translation factors required for 
efficient translation initiation. These include the RNA helicase eIF4A, the poly (A)-binding 
protein (PABP), and eIF3, which recruits the 40S ribosome to the 5” end of the mRNA. 
4EBP1 and eIF4G have overlapping binding sites in eIF4E and, therefore, compete for 
binding to eIF4E (after (Wang et al. 2008)). 
Cyclin D1 is considered to be the prime downstream target protein for eIF4E-
dependent protein translation. Expression of eIF4E significantly correlates with 
increased cyclin D1 protein translation. eIF4E enhances nuclear export of cyclin D1 
mRNAs (Mamane et al. 2004; Culjkovic et al. 2005). Targeting eIF4E with antisense 
oligodeoxynucleotides (ASO) or ribavirin diminished the expression of eIF4E-
dependent proteins such as cyclin D1. Additionally, it has been shown that inhibition 
of mTOR signaling was associated with reduction of cyclin D1 expression (Dong et 
al. 2005; Averous et al. 2008; Yu et al. 2008).  
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Cyclin D1 has been shown to be implicated in several cancer types. Cyclin D1 is a 
key regulator of the G1 phase of the cell cycle, which drives cells through the G1/S 
phase transition (Stacey 2003). Downregulation of cyclin D1 function results in cell 
cycle arrest in G0/G1 cell cycle phase. 
1.2.2.7 Regulation of protein serine/threonine phosphatase 
mTOR directly phosphorylates p70S6K and 4EBP1, and also indirectly increases 
their phosphorylation by inhibition of protein serine/threonine phosphatase (Dufner et 
al. 1999). 
The two main classes of serine/threonine protein kinases, PP1 and PP2A, are 
extensively involved in many signaling pathways. Treatment of cells with 
phosphatase inhibitors calyculin A prevents 4EBP1 dephosphorylation. At the same 
time, inhibition of p70S6K activity by rapamycin, curcumin or amino acid deprivation 
requires phosphatase activity (Peterson et al. 1999; Yu et al. 2008). The 
serine/threonine phosphatase PP2A is a prime candidate for such a mTOR-
dependent phosphatase. PP2A dephosphorylates p70S6K in vitro and associates 
with full-length p70S6K, rather than the rapamycin-resistant N- and C-terminal 
truncated p70S6K mutant (Peterson et al. 1999). 
The role of phosphatase in mTOR signaling has been previously identified. Tap42, a 
protein phosphatase 2A (PP2A) regulatory subunit, is essential for mTOR-mediated 
signaling in yeast. Tap42 interacts with the catalytic subunits of type 2A phosphatase 
(PP2Ac), including Pph21 and Pph22, and several 2A-like phosphatases, such as 
Sit4, Pph3 and Ppg1. In cells under poor nutrient conditions, Tap42 is dissociated  
from the phosphatases. However, even under optimal growth conditions, Tap42 
associates only with a small portion of the phosphatases. For instance, only 5–10% 
of Sit4 and PP2Ac is found to associate with Tap42 in actively growing cells. Tap42 
acts as a phosphatase inhibitor, which binds and inhibits phosphatases in response 
to mTOR signaling activity (Di Como et al. 1996; Yan et al. 2006).  
In more details, mTOR in the presence of sufficient nutrients directly phosphorylates 
TIP41, which causes release of TAP42. TAP42 can now bind to the catalytic subunit 
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of PP2A type phosphatases (Sit4, PPh21/22). Association of TAP42 with PP2A 
prevents its binding to the regulatory subunits A and B, and, thus, leads to inhibition 
of PP2A downstream phosphorylation. In the absence of nutrients or in the presence 
of rapamycin, mTOR does not phosphorylate TIP41. TIP41 can now bind to TAP42 
and this binding prevents the association of TAP42, leading to binding of PP2A with 
subunits A and B and dephosphorylation of downstream targets. This results in 
inhibition of translation and transcription (Rohde et al. 2001)(Figure 8). 
Mammalian cells also contain a homolog of Tap42, the α4 protein, which associates 
with PP2A phosphatases and modifies the substrate specificity of PP2A (Murata et 
al. 1997). The regulation of this complex may differ from that in yeast, as a recent 
study has suggested that PP2A is the target of mTOR. The p70S6K was found in a 
complex with a fraction of PP2A, and a model has been proposed, by which mTOR 
phosphorylation of PP2A results in phosphatase inactivation that prevents p70S6K 
dephosphorylation (Peterson et al. 1999; Rohde et al. 2001). In addition, TAP42 and 
α4 protein interfere with PP2A in vitro inducing dephosphorylation of 4EBP1 
(Nanahoshi et al. 1998). On another hand, rapamycin treatment neither induced 
restoration of the phosphatase activity of PP2A nor did it cause dissociation of 
alpha4 and Tap42 from PP2A (Nanahoshi et al. 1998). 
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Figure 8. Model for mTOR regulation of PP2A activity 
In the presence of sufficient nutrients mTOR directly phosphorylates TIP41, which causes 
release of TAP42. TAP42 can now bind to the catalytic subunit of PP2A type phosphatases 
(Sit4, PPh21/22). Association of TAP42 with PP2A prevents its binding to the regulatory 
subunits A and B, thus, leading to inhibition of PP2A downstream phosphorylation. In the 
absence of nutrients or in the presence of rapamycin, mTOR does not phosphorylate TIP41. 
TIP41 can now bind to TAP42 and this binding prevents the association of TAP42 leading to 
binding of PP2A with subunits A and B and dephosphorylation of downstream targets 
resulting in inhibition of translation and transcription (after (Rohde et al. 2001)).  
 
 
 
 
 
INTRODUCTION 
 
 
21 
 
1.2.3 mTOR related diseases and the challenges associated with targeting 
mTOR 
Recent studies confirmed that the mTOR signaling pathway involved in various 
pathological disorders. The importance of the mTOR pathway in different human 
diseases including cancer is due to its elevated activity and the biological effects of 
its downstream target proteins, many of which promote cell survival, proliferation and 
growth. Therefore, the development of small molecules, which modulate the mTOR 
pathway, has translational potential into therapy. 
Typically, mTOR hyperactivation is caused by inactivating mutations of certain 
suppressors genes in the mTOR signaling pathway like the TSC1/TSC2 complex, 
LKB1 or PTEN, resulting in mTOR-dependent cell growth. 
The macrolide rapamycin is the classical inhibitor of the mTOR signaling pathway. 
The compound possesses immunosuppressive, antifungal and antitumor properties. 
 
1.2.3.1 Tuberous sclerosis complex (Hamartomas)   
Tuberous sclerosis complex (TSC) is an autosomal dominant multisystem disorder 
characterized by widespread hamartomas in several organs, including the brain, 
heart, skin, kidney, lung, and liver. TSC is caused by heterozygous mutations in the 
TSC1 or TSC2 gene (Kwiatkowski et al. 2005). 
Hamartomas are benign focal tumour-like malformations. Hamartomas are defined 
as lesions that are (1) commonly present at birth, but can also be acquired (2) and 
are composed of aberrant mature or nearly mature structures. Unlike neoplasms, 
hamartomas lack the ability to grow continuously, resulting in a self-limiting 
proliferation. Hamartomas tend to originate from the lung, liver, spleen, kidney, and 
intestine, but uncommon examples have been noted in various other organs. Cell 
lacking TSC1/TSC2 exhibit activation of the mTOR signaling pathway (Chan et al. 
2004; Kwiatkowski et al. 2005), which is thought to contribute to the clinical 
syndromes in TSC (Chan et al. 2004) . Preclinical data and phase I/II clinical trials 
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suggest that the use of mTOR inhibitors is beneficial in TSC patient (Lee et al. 2005; 
Sampson 2009). 
1.2.3.2 Hamartoma related syndromes 
Cowden disease, Bannayan-Riley-Ruvalcab syndrome (BRRS), proteus syndrome 
and Lhermitte-Duclos disease are hamartoma syndromes that share similarity to 
TSC, although they result from inactivating mutation in the tumor suppressor PTEN. 
PTEN-deficiency results in TSC1/TSC2 inhibition and subsequence hyperactivation 
of mTORC1. Recent studies indicated that mTOR inhibition with rapamycin may 
represent a suitable therapeutic option for the chemoprevention and treatment of 
Cowden disease patients and other tumor syndromes that involve defective PTEN 
function (Inoki et al. 2005; Squarize et al. 2008).  
Peutz-Jeghers syndrome (PJS) is associated with hamartomas in the gastrointestinal 
tract. Recently, PJS was linked to the TSC-mTOR pathway. The gene mutated in 
this syndrome, STK11, encodes a protein kinase that phosphorylates and activates 
LKB1- AMPK signaling, an essential positive regulator of the TSC1/TSC2 complex. 
Recently it has been shown that rapamycin effectively suppresses Peutz-Jeghers 
polyposis in a mouse model, suggesting that rapamycin or its analogues may 
represent a new targeted therapy for the treatment of PJS (Inoki et al. 2005; Wei et 
al. 2008). 
1.2.3.3 Polycystic kidney disease 
Polycystic kidney disease (PKD) is generally a late-onset multisystem disorder 
characterized by large cysts in one or both kidneys and a gradual loss of normal 
kidney tissue, which can lead to chronic renal failure. The most common form is 
autosomal dominant polycystic kidney disease (ADPKD). ADPKD is caused by 
mutations in the PKD1 and PKD2 gene, which encode polycystin-1 (PC-1) and -2 
(PC-2), respectively. TSC2 gene and PDK1 gene genes are located in close vicinity 
on the human chromosome 16 in a tail-to-tail orientation. Genetic molecular analysis 
has revealed that, in the majority of cases of severe polycystic kidney disease in 
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TSC revealed large deletions of chromosome 16 affecting both the TSC2 and the 
PKD1 gene. Indeed, TSC1 inactivation in the kidney results in massive renal 
cystogenesis (Boletta 2009).  
In animal models for ADPKD, hyperactivation of mTOR was observed and mTOR 
inhibition could indeed retard cyst formation and progression of renal failure, which 
suggests that mTOR activity is the molecular mechanism underlying renal cyst 
formation (Tao et al. 2005). Recently, hyperactivated mTOR was found in cyst-lining 
epithelial cells in human ADPK patients and it was shown that treatment of human 
ADPKD transplant-recipient patients with rapamycin results in a significant reduction 
in native polycystic kidney size (Shillingford et al. 2006). It has also been recently 
demonstrated that rapamycin might be an effective therapeutic option for ADPKD 
patients that are prone to progress to end-stage renal disease (Serra et al. 2007). 
1.2.3.4 Neurodegenerative disorders 
It has been shown that the mTOR signaling pathway is associated with many 
neurological disorders (mental retardation syndromes, autism, Alzheimer’s, 
Huntington’s and Parkinson`s diseases) (Swiech et al. 2008; Hoeffer et al. 2010) 
Autophagy is an intracellular bulk degradation process through which a portion of the 
cytoplasm is delivered to lysosomes for degradation. Thus, autophagy is the 
protective mechanism by which our body can fight against these neurodegenerative 
diseases, because these diseases develop from intracellular protein aggregations 
associated with mutant proteins (Mizushima 2005; Hara et al. 2006). 
Interestingly, induction of autophagy by inhibition of the mTOR signaling pathway 
enhances the autophagic clearance of protein aggregates (Hara et al. 2006).  
In a mouse model of Huntington disease, rapamycin attenuates huntingtin 
accumulation and cell death, Furthermore, rapamycin protects against 
neurodegeneration in a fly model of Huntington disease, and the rapamycin analog 
CCI-779 improved the performance on four different behavioral tasks and decreased 
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the aggregate formation in a mouse model of Huntington’s disease (Ravikumar et al. 
2004). 
Moreover, treatment of a mouse model for Parkinson’s disease with rapamycin 
prevents the development of dyskiesia (L-DOPA-motor side effect). Thus, mTOR 
inhibitors represent a promising target for the design of anti-parkinsonian therapies 
(Santini et al. 2009). 
1.2.3.5 Cancer 
The term cancer designates diseases with uncontrolled cell division resulting in local 
tumor or neoplasia formation. Cancer cells can also spread to other parts of the body 
through the blood or lymphatic systems. 
Tumor suppressor genes are normal genes that slow down cell division, repair DNA, 
and eventually induce cells to die (a process known as apoptosis or programmed cell 
death). When tumor suppressor genes do not work properly, cells may grow out of 
control, leading to cancer. Many different tumor suppressor genes have been 
identified, including PTEN, p53, BRCA1, BRCA2, APC, and RB1.  
Increased mTOR signaling pathway activity can occur by a number of mechanisms. 
A common mechanism is the loss of function of the tumor suppressor gene PTEN by 
mutation, deletion or silencing. The signaling pathways that regulate mTOR activity 
are frequently activated in human cancers (Sawyers 2003; Wan et al. 2007)  (Table 
2). The main mechanism by which mTOR can contribute to cancer development is 
through its effects on cell cycle progression and its anti-apoptotic activity. mTOR is 
required for cell cycle progression, and inhibition of mTOR activity by rapamycin 
arrests cells in the G1 phase of the cell cycle. Expression of a rapamycin-resistant 
mutant of mTOR reduces the effect of rapamycin on the cell cycle progression. 
There is evidence that the effect of rapamycin on the cell cycle progression occurs 
by the inhibition of the downstream effectors of mTOR, p70S6K, and eIF4E. 
Moreover, inhibition of mTOR drives the cell into apoptosis. Many proteins in mTOR 
signaling pathway have already been implicated in cancer (Sawyers 2003; Wan et al. 
2007). Therefore, the development of anti-cancer drugs related to the mTOR 
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pathway is consered to be very promising. Thus, clinical trials have already been 
started or conducted using mTOR inhibitors such as rapamycin, RAD001, CCI-799 
and AP23579, for cancer treatment. 
In clinical trials, rapamycin and three rapamycin analogues, CCI-779 (Temsirolimus), 
RAD001 (Everolimus), and AP23573 (Deforolimus) have been assessed for their 
efficacy as anticancer agents (Wan et al. 2007). Rapmycin tested in recent clinical 
studies for treatment of patients with recurrent PTEN-deficient glioblastoma, phase 1 
clinical trial (Cloughesy et al. 2008). Rapamycin analogues were used in clinical trials 
for treatment of different cancers type (Table 3). Rapamycin and RAD001 can be 
administered orally. Yet, pharmacokinetic studies showed that both drug have low 
bioavailability. Therefore, the use of rapamycin as anticancer might be impractical, 
because of its poor water solubility and stability in solution. On the other hand, CCI-
779 and AP23573 can be administered intravenously. CCI-779 was recently 
approved by U.S Food and Drug Administration (FDA) for treatment of renal cell 
carcinoma (Ballou et al. 2008; Morgan et al. 2009). 
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Table 2. Proteins in the mTOR signaling pathway already implicated in cancer 
(Sawyers 2003; Wang et al. 2007) 
Protein Dysfunction Type of cancer 
Upstream of mTOR 
PTEN Mutation, deletion, or promoter 
methylation 
Brain, bladder, breast, 
prostate, endometrial 
cancer, and 
glioplastoma 
Akt Gene amplification Gastric 
adenocarcinoma, 
overian, breast, and 
pancreatic cancers 
TSC1/TSC2 Gene mutation TSC syndrome 
Downstream of mTOR 
eIF4E Gene amplification; protein over 
expression 
Many human cancer 
types 
p70S6K Gene amplification Breast, ovarian cancers 
Cyclin D1 Gene amplification Mantle cell lymphoma 
and breast cancer 
Myc Gene amplification Burkitt´s lymphoma 
Other Myc-driven 
cancer 
HIF Gene amplification Kidney cancer 
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Table 3. Clinical trials with mTOR inhibitors as anticancer agents (Wan et al. 2007; 
Cloughesy et al. 2008) 
Compound cancer Trial phase 
Rapamycin  Recurrent PTEN-deficient 
glioblastoma 
Phase I 
CCI-779 Refractory renal cancer, 
advanced breast cancer, mantle 
cell lymphoma, recurrent 
glioblastoma, advanced renal 
cancer 
Phase II 
RAD001 Advanced solid cancer and 
metastatic renal cancer 
 
Phase I 
AP23574 Advanced sarcomas and relapsed 
hematologic cancer 
Phase II 
1.2.3.6 Other disorders and drug resistances 
The mammalian target of rapamycin (mTOR) acts as a central regulator of ribosome 
biogenesis, protein synthesis, cell growth, cell survival, cytoskeletal organization and 
most cell activities. 
Dysregulation of mTOR signaling has been reported to be involved in cardiac 
hypertrophy (Inoki et al. 2005). It also plays an important role in metabolic disorders 
like obesity, type 2 diabetes, non-alcoholic fatty liver disease and Niemann-Pick type 
C (NPC) disease (Pacheco et al. 2008; Laplante et al. 2009). 
A recent animal study revealed that the mTOR signaling pathway links diet-induced 
obesity with vascular senescence and cardiovascular diseases (Wang et al. 2009). 
Moreover, it has been shown that inhibition of the mTOR signaling pathway 
extended the lifespan in inverteberates (yeast, nematodes and fruits) and also in 
mammalians species (mice) (Harrison et al. 2009). Thus,the  mTOR signaling 
pathway appears to be a key target to control many diseases. 
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Previous studies showed that the mTOR signaling pathway is implicated in the 
resistance to many anticancer drugs such as retinoic acid, vincristine and 
trastuzumab (Jiang et al. 2008) 
1.3 Apoptosis and mTOR signaling 
Apoptosis is the balance between pro- and antiapoptotic proteins. Defects in the 
apoptotic machinery are mainly due to either overexpression of antiapoptotic 
proteins (i.e. Bcl-2, Bcl-xL and survivin) or decrease of proapoptotic proteins (i.e. 
BAX and BAK, NBK/Bik, BAD, Par-4, Bim, cytochrome c, apoptosis-inducing factor 
(AIF)) resulting in uncontrolled growth and proliferation.  
Many studies showed that activation of the mTOR signaling pathway is implicated in 
a decreased expression of proapoptotic proteins. Consistently, mTOR inhibitors 
induced apoptosis in different cell lines through upregulation of proapoptotic proteins 
and at the same time downregulation of antiapoptotic proteins. (Shinjyo et al. 2001; 
Tirado et al. 2005; Freilinger et al. 2006; Yan et al. 2006; Zhang et al. 2007; 
Wangpaichitr et al. 2008; Hayun et al. 2009). 
Eukaryotic initiation factor 4E (eIF4E), downstream of mTOR, is responsible for cap-
dependent translation and exhibits anti-apoptotic activity (Mamane et al. 2007). 
Consistently, it has been shown that eIF4E mediates resistance to apoptosis via 
increases cap-dependent translation (Herbert et al. 2000; Larsson et al. 2006). 
Additionally, it has been shown that targeting eIF4E with specific RNAi or eIF4E-
binding peptides is able to induce apoptosis (Herbert et al. 2000; Dong et al. 2009).  
The main biochemical hallmark of apoptosis is activation of caspase-3. Interestingly, 
caspase-dependent apoptosis is an important mechanism of cell death when the 
rapamycin derivative RAD001 is combined with 3 Gy radiations (Albert et al. 2006), 
Additionally, rapamycin can induce caspase-3 activation and induce apoptosis 
dependent on caspase-3 activation (Zhang et al. 2006). 
All these findings indicate that the mTOR signaling pathway is an important target for 
the development of novel drugs for diseases-associated with apoptosis defect.  
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1.4 Aims of the study 
We have previously shown that the pentacyclic triterpenoid acetyl-11-keto-ß-
boswellic acid (AKβBA) induces apoptosis in vitro and in vivo (Syrovets et al. 2005). 
In comparison to AKβBA, the deacetylated derivative 11-keto-ß-boswellic acid (KBA) 
showed a decreased activity, pointing to the importance of the acetyl group at carbon 
number 3 of ring A.  
The aim of present study was to,  
i) synthesize a new ester derivative of KBA with enhanced proapoptotic activity, 
ii) Clarify the putative antiproliferative effect of the new compound, 
iii) Shed light on the type of cell death induced, and to 
iv) Elucidate the mechanism behind this cell death.  
MATERIALS & METHODS 
 
 
30 
 
2. MATERIALS and METHODS 
2.1 Synthesis of 3-cinnamoyl-11-keto-β-boswellic acid (C-KβBA) 
Materials 
The synthesis of the corresponding new substance followed a common published 
method for esterification (Steglich reaction) (Neises et al. 1978), whereas the starting 
compound 11-keto-β-boswellic acid was extracted from a commercial oleogum resin 
of Boswellia carterii (Caesar & Lorentz GmbH; Hilden, Germany; batch number 
72598287, tested corresponding to EB6) according to the method of Winterstein and 
Stein (Winterstein et al. 1932). The identity of the isolated 11-keto-β-boswellic acid 
was verified by MS and NMR analysis as described (Büchele et al. 2003). Cinnamic 
acid (19 mg, 84 µmol), 11-keto-β-boswellic acid (20 mg, 42 µmol), 
dicyclohexylcarbodiimide (17 mg, 84 µM) and dimethyl amino pyridine (4 mg, 21 
µmol) were dissolved in 5 ml dry dichloromethane. This solution was stirred for 17 h 
at room temperature. The end of the reaction was controlled by a specific thin layer 
chromatography separation system. The precipitate was separated by filtration and 
the filtrate was evaporated with argon to dryness. After the residue was redissolved 
in methanol, 3-cinnamoyl-11-keto-β-boswellic acid was precipitated by addition of 
water. The precipitate was washed with water and purified by semipreparative 
reversed phase HPLC to chemical homogeneity (Belsner et al. 2003). The yield of 
the reaction was 70%. Mass spectra were recorded with a Finnigan SSQ 7000 
single-stage-quadrupol mass spectrometer in negative chemical ionization (CI) 
mode. The scanned mass range was 10u to 2000u. 1-D-NMR and 2D-NMR spectra 
were recorded on a Bruker AVANCE 400 with a 5 mm QNB 1H/13C/31P/13F NMR 
probe and 5 mm BBI 1H-BB z-GRD NMR probe, respectively. 
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2.2 Cell culture 
Materials 
Androgen-independent      
PC-3 
ATCC (Teddington, UK) 
Androgen-independent       
PC-3 PTEN 
Professor Derek LeRoith, Professor of Medicine, 
Endocrinology Diabetes and Bone Disease 
Director of Metabolism Mount Sinai School of 
Medicine, New York City 
Androgen-dependent           
LNCaP 
ATCC (Teddington, UK) 
Androgen-independent       
DU 145 
ATCC (Teddington, UK) 
Epithelial cell from normal 
prostate (RWPE-1) 
ATCC (Teddington, UK) 
Breast cancer cell line               
MDA-MB-231 
ATCC (Teddington, UK) 
 
Mouse embryonic fibroblasts 
MEFs (TSC-/-) 
MEFs (TSC+/+) 
Professor David J. Kwiatkowski, Professor of 
Medicine, Brigham and Women's Hospital, Harvard 
Medical School 
F-12K medium Invitrogen, Karlsruhe, Germany 
RPMI 1640 medium PAA Laboratories GmbH, Austria 
MEM medium Invitrogen, Karlsruhe, Germany 
Keratinocyte-SFM medium  Invitrogen, Karlsruhe, Germany 
DMEM medium Invitrogen, Karlsruhe, Germany 
DMEM/F-12 medium Invitrogen, Karlsruhe, Germany 
EDTA (Titriplex III) Merk KG, Darmstadt, Germany 
Penicillin/streptomycin  Invitrogen, Karlsruhe, Germany 
FCS “fetal calf serum” Seromed, Berlin, Germany 
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Protocol 
Cultivation 
Cell lines Medium 
PC-3 F-12K, 10% FCS, 1X penicillin streptomycin 
PC-3 PTEN F-12K, 10% FCS, 500 µg/ ml geneticin 
LNCaP RPMI-1640, 10% FCS, 1X penicillin streptomycin, 
1 mM sodium pyruvate, 2 mM L glutamate and 4.5 
g/L glucose 
DU 145 MEM,10% FCS, 1X penicillin streptomycin, 1 mM 
sodium pyruvate, 2 mM L glutamate and 1X non- 
essential amino acids (NEAA) 
RWPE-1 Keratinocyte-SFM, 0.05 mg/ml bovine pituitary 
extract (BPE), 5 ng/ml human recombinant 
epidermal growth factor (EGF). 
MDA-MB-231 Leibovitz's L-15 Medium, 10% FCS. 
MEFs (TSC-/-) 
MEFs (TSC+/+) 
DMEM, 10% FCS, 1X penicillin streptomycin. 
and 
DMEM/F-12, 10% FCS, 1X penicillin streptomycin, 
1 mM sodium pyruvate, 4 mM L glutamate and 4.5 
g/L glucose (for XTT assay) 
 
Each cell line was cultivated according to data sheet from the cell bank. 
Subculturing 
The splitting ratio was 1:3 to 1:6 with medium renewal 2 to 3 times per week. 
 
MATERIALS & METHODS 
 
 
33 
 
Freezing and thawing  
Cells (3 x 106)/cryovial in 1.5 ml freezing medium (medium containing 10% DMSO) 
were frozen in an isopropanol box at -80oC for 24 h, then stored in the vapor phase 
of liquid nitrogen. 
The contents of a cryovial was thawed and suspended in 30 ml prewarmed complete 
medium. The culture was allowed to grow for at least 2 weeks before any 
experiments. 
2.3 Antiproliferative effect of C-KβBA in vitro   
2.3.1 Cell proliferation assay (XTT assay) 
The assay is based on the measurement of the metabolization of tetrazolium salts 
(XTT, Roche Diagnostics) to water-soluble formazan salt by viable cells 
(mitochondrial reduction of tetrazolium salt). 
Materials 
C-KβBA, KBA, Methyl-KBA, AKβBA, 
cinnamic acid 
B. Büchele 
Institute of Pharmacology of Natural Products  
& Clinical Pharmacology, Ulm University,  
Germany 
Akt inhibitor VIII Calbiochem, San Diego, USA 
Temsirolimus (CCI-779) LC laboratories, Woburn, USA 
Rapamycin Sigma-Aldrich, Steinheim, Germany 
Cell proliferation Kit (XTT) Roche Diagnostics, Mannheim, Germany 
Microtiter plate BD, Falcon, San Jose, USA 
ELISA reader Dynatech MR 7000, Germany 
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XTT labeling mixture 
125 µM sodium XTT  
25 µM phenazine methosulfate 
Protocol 
The indicated cell lines (in 200 µl of culture medium/ well) were seeded in a 96-well 
plate (flat bottom), treated with or without compounds, and incubated for various time 
periods at 37°C in a 5% CO2 atmosphere. Before the end of the experiment, 50 µl of 
XTT labeling mixture was added per well and the plates were incubated for another 
4 h at 37°C in 5% CO2. The spectrophotometric absorbance of the sample was 
measured using a microtiter plate (ELISA) reader at 450 nm and a reference filter 
630 nm. 
2.3.2 Clonogenic survival assay 
The clonogenic assay is based on the ability of a single cell to grow into a colony. It is also 
the method of choice to determine the effectiveness of the cytotoxic agents over a long 
period of time.  
Materials 
Methanol Sigma-Aldrich, Steinheim, Germany 
Acetic acid VMR International S.A.S, France 
Crystal violet Sigma-Aldrich, Steinheim, Germany 
PBS Gibco, Karlsruhe, Germany 
Spectrophotometer Dynatech MR 7000, Germany 
Fixation solution 
10% Methanol 
10% Acetic acid 
Staining solution 
0.4% Crystal violet 
20% Methanol 
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Protocol 
PC-3 cells were harvested from cultures growing in the log-phase and were plated at 
a density of 3000 cells/well in a 6-well plate. After 24 h, the cells were treated with C-
KβBA or 0.5% DMSO (as control) in 1% FCS. On the third day, the medium was 
removed and new medium (10% FCS) was added. After 6 days, the wells were 
washed twice with ice-cold PBS and fixed for 10 min in 1 ml fixation solution. 
Colonies were stained with 1 ml staining solution for 10 min. The staining solution 
was removed and the wells were washed with water to remove excess dye, and 
dried at room temperature overnight. Photos of the plates were taken, and the 
colonies were subsequently solubilized in 33% acetic acid followed by 
spectrophotometric analysis at 540 nm. 
2.3.3 Antiproliferative effect of C-KβBA in vivo 
We used the chick embryo chorioallantoic membrane as a bioassay to investigate 
the cytotoxicity and apoptotic parameters of C-KβBA in vivo. 
Materials 
Anti Ki-67 antibody DAKO, Glostrup, Denmark   
TUNEL Kit Roche Diagnostics, Mannheim, Germany 
Anti p-p70S6K antibody Epitomics, Hamburg, Germany 
Protocol 
For the application of the compound in the xenograft model, PC-3 cells were grafted 
into silicone rings placed onto the chorioallantoic membrane (CAM) of chicken eggs. 
The fertilized chicken eggs were incubated at 37°C at constant humidity (Syrovets et 
al. 2005). On day six, 0.7 × 106 PC-3 cells in the log growth phase were seeded in 
20 µl medium/Matrigel (1: 1, v/v) in 6 mm silicone ring were placed onto the CAM. 
Starting from day 2 after seeding, the cells were topically treated once daily either 
MATERIALS & METHODS 
 
 
36 
 
with 20 µl compound or 0.5% DMSO alone (control). On day 12, the xenografts were 
histologically analyzed. 
 
 
 
Figure 9. Application of compounds onto the chorioallantoic membrane (CAM) of a fertilized 
chicken egg. 
 
2.4 Analysis of apoptosis parameters 
2.4.1 Expression of phosphatidylserine on the cell surface 
Apoptosis is characterized by a variety of morphological features such as loss of 
membrane asymmetry and attachment, condensation of the cytoplasm and nucleus, 
and internucleosomal cleavage of DNA. One of the earliest indications of apoptosis 
is the translocation of the membrane phospholipids’ phosphatidylserine (PS) from 
the inner to the outer leaflet of the plasma membrane. Once, it exposed to the 
extracellular environment, binding sites on PS become available for annexin V, a 35-
36 kDa, Ca+-dependent, phospholipid-binding protein with a high affinity for PS. 
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Figure 10. Schematic representation of phosphatidylserine (PS) phospholipid flipping to the 
outer membrane leaflet during apoptosis and subsequent binding of exogenously 
added annexin V to the cell surface 
    (http://www.bdbiosciences.ca/canada/pharmingen/product_pages/annexinv/) 
Materials 
Annexin V-FITC   Roche Diagnostics, Mannheim, Germany 
PBS (with 2 mM CaCl2) Gibco, Karlsruhe, Germany 
Propidium iodide Sigma-Adlrich, Steinheim, Germany 
FACScan  Becton Dickinson, Franklin Lakes, USA 
Citric acid solution 
1.35 M potassium chloride  
0.15 M sodium citrate  
Binding buffer 
     500 ml Sterofundin (B. Braun Avitum AG, Melsungen, Germany) 
5 ml 1 M HEPES 
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Protocol 
PC-3 cells were exposed to the desired concentrations of C-KβBA for 24 h. 
Subsequently both, floating and adherent cells, were collected. The floating cells 
were collected by centrifugation at 400 x g for 5 min, whereas adherent cells were 
harvested by citric acid solution and collected by centrifugation at 400 x g for 5 min. 
The pooled cells were resuspended in F-12K medium (10% FCS) and incubated for 
20 min at 37°C. Then the cells were collected by centrifugation at 400 x g, 
resuspended in 100 µl of binding buffer, and mixed with annexin V-FITC and 
propidium iodide according to the manufacturer’s instructions. In cells undergoing 
apoptosis annexin V binds to PS, which is translocated from the inner to the outer 
leaflet of the cytoplasmic membrane. Double staining is used to distinguish between 
viable, early apoptotic and necrotic or late apoptotic cells. Untreated control cells 
were also included in the analysis. Annexin V-FITC signals were recorded in FL1-H 
and propidium iodide in FL2-H. Cells in the bottom left quadrant (annexin V-negative, 
propidium iodide-negative) are viable, whereas cells in the right lower quadrant 
(annexin V-positive, propidium iodide-negative) are in the early stages of apoptosis, 
and the cells in the top right quadrant (annexin V-positive, propidium iodide-positive) 
are in later stages of apoptosis and necrosis. 
2.4.2 Measurement of caspase activity 
Caspases (cysteine-aspartic acid proteases) are a family of cysteine proteases, 
which play essential roles in apoptosis. A member of this family, caspase 3 (CPP32, 
apopain, YAMA) has been identified as a key effector caspase of apoptosis of 
mammalian cells. Capase 3 activity was determined by proteolytic cleavage of the 
fluorogenic substrate (Z-DEVD–R110), which leads to formation of a fluorescent 
product that can be measured fluorimetrically. 
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Materials 
Fluorogenic substrate 
Z-DEVD–R110 substrate 
Molecular Probes/Invitrogen, 
Karlsruhe, Germany 
QuantaMaster™ UV VIS  
spectrofluorometer 
Photon Technology International, 
Birmingham, NJ, USA 
20x Cell lysis buffer 
200 mM Tris-HCl, pH 7.5 
2 M NaCl, 20 mM EDTA 
0.2% TRITON X-100 
5x Reaction buffer 
50 mM PIPES, pH 7.4 
10 mM EDTA 
0.5% CHAPS 
1 M DTT 
Protocol 
PC-3 cells (1 x 106) cultivated in F-12K medium for 24 h were treated with or without 
different concentrations of C-KβBA for 24 h, collected, and caspase activity was 
analyzed according to the manufacturer’s protocol. Briefly, PC-3 cells were 
resuspended in 50 µL 1x cell lysis buffer on ice. After 30 min, 50 µL 2x reaction 
buffer (containing 10 mM DTT and 50 µM caspase substrate) was added and 
incubated for 30 min at room temperature. The samples were measured with a 
fluorescence spectrophotometer (496 nm/520 nm).  
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 Agarose Gel  
2.4.3 Measurement of DNA fragmentation 
DNA fragmentation is a key feature of programmed cell death. Apoptosis is 
characterized by the activation of endogenous endonucleases with subsequent 
cleavage of chromatin DNA into internucleosomal fragments of 180-200 BP and 
multiples thereof.  
  
Figure 11. Scheme of the DNA fragmentation process and its analysis 
Materials 
PBS Gibco, Karlsruhe, Germany 
RNase A  Sigma-Aldrich, Steinheim, Germany 
Proteinase K Sigma-Aldrich, Steinheim, Germany 
Agarose Invitrogen, Karlsruhe, Germany 
Photo apparatus easy 429 Herolab, Wiesloch, Germany 
UV-Photometer Herolab, Wiesloch, Germany 
Electrophoresis apparatus Biometra, Göttingen, Germany 
Genomic DNA extraction buffer 
5 mM Tris-HCl, pH 8.0 
20 mM EDTA 
0.8% (w/v) SDS 
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Electrophoresis buffer 
TBE (Tris/borate/EDTA) buffer, 5x 
445 mM Tris base 
445 mM boric acid 
10 mM EDTA, pH 8.0 
 
6x Loading buffer 
3 ml glycerol (30%)  
25 mg bromophenol blue (0.25%)  
 dH2O to 10 ml 
 
Protocol 
PC-3 cells were cultured for 24 h in F-12K medium, 10% FCS, and then treated with 
or without C-KβBA in medium/1% FCS for 96 h with daily medium changes. Floating 
cells were collected by centrifugation, washed with PBS, and lysed with 20 µl 
genomic DNA extraction buffer with 2 µl RNAse (50 mg/ml)) at 37oC for 30 min with 
shaking, then 10 µl proteinase K (20 mg/ml) were added, and incubated at 50oC for 
90 min with shaking. Then genomic DNA extractions were analyzed by 
electrophoresis on a 1.5% agarose gel run at 50 V for 4 h. After staining with 
ethidium bromide (1 µg/ml), the presence of DNA ladders could be visualized under 
UV light. 
2.5 Cell cycle analysis 
The DNA contents of cells can provide information about the cell cycle and 
consequently the effect of added stimuli on the cell cycle, e.g. after drug treatment. 
The most commonly used DNA dye is propidium iodide, which intercalates in the 
DNA helix and fluoresces strongly red. Propidium iodide is excited at 488 nm, and 
can be analyzed on most common flow cytometers. Propidium iodide also stains 
double-stranded RNA. Therefore, the latter has to be removed with ribonucleases. 
The progression of cells through the cell cycle was examined using flow cytometry. 
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Figure 12. Scheme of flow cytometric cell cycle analysis 
 (Modified: http://upload.wikimedia.org/wikipedia/commons/2/22/Cell_Cycle_2.png) 
Materials 
Ethanol Merck, Darmstadt, Germany 
PBS Gibco, Karlsruhe, Germany 
Propidium iodide Sigma-Aldrich, Steinheim, Germany 
RNase A  Sigma-Aldrich, Steinheim, Germany 
Flow cytometry  FACScan, Becton Dickinson, Franklin 
Lakes, NJ, USA 
CellQuest software 
 
Modfit software 
Becton and Dickinson, Franklin Lakes, NJ, 
USA 
Becton and Dickinson, Franklin Lakes, NJ, 
USA 
Propidium iodide staining buffer 
1x PBS 
50 µg/ml propidium iodide 
40 µg/ml DNase-free RNase A 
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Protocol 
Cells were either left untreated or treated with C-KβBA for 24 h in 1% FCS medium, 
then harvested by trypsinization, collected by centrifugation 400 x g for 5 min, fixed 
in 70% ethanol ( -20°C overnight) and washed once with PBS. After centrifugation, 
the cells were resuspended in 1 ml of propidium iodide solution. The cells were 
incubated at room temperature for 30 min in the dark, and the DNA contents were 
analyzed using the flow cytometer and CellQuest software. The data were analyzed 
with Modfit software. 
2.6 Protein phosphatase assay 
Serine/threonine phosphatase activity was determined using malachite green 
phosphatase assay. This assay is a non-radioactive serine/threonine phosphatase 
assay, which measures free inorganic phosphate (Pi) that is released from a 
phosphopeptide substrate. The free inorganic phosphate reacts with malachite green 
to form an ammonium molybdate-malachite green phosphate complex, which 
absorbs at or near 620 nm. 
Materials 
Protein phosphatase peptide substrate  
H-Arg-Arg-Ala-pThr-Val-Ala-OH,  
(RRApTVA, K-R-pT-I-R-R) 
Enzo Life Sciences GmbH, Lörrach 
Germany 
 
Protease inhibitor cocktail (P1860) Sigma-Aldrich, Steinheim, Germany 
Malachite green solution A 
10 mM ammonium molybdate,  
1 N HCl  
3.4% ethanol 
 0.034% malachite green 
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Phosphatase lysis buffer 
20 mM HEPES (pH 7.4) 
0.1% NP-40  
0.1 mM MgCl2 
1 mM EGTA  
30 mM β-mercaptoethanol (BME) 
1 mM phenylmethylsulfonyl  
fluoride (PMSF) 
Protease inhibitor cocktail 
Freshly added 5 µl PMSF, 10 µl 
protease inhibitor cocktail and 2.4 µl 
BME to 1 ml buffer 
Malachite green additive (solution B) 
1% Tween®-20 
 
Phosphate assay buffer 
50 mM Tris-HCl (pH 7.0) and 0.1 mM 
EDTA 
200 µM phosphopeptide substrate  
Malachite green detection solution 
1 ml solution A 
10 µl solution B 
 
Protocol 
PC-3 cells, 0.2 x 106, were cultivated in 6-well plates for 24 h in 10% FCS medium 
followed by overnight starvation in 0% FCS medium. The cells were pretreated with 
calyculin A for 20 min, then treated with C-KβBA in the presence or absence of 
calyculin A for 30 min. The cells were activated by 1% FCS for 30 min. After that the 
cells were washed with 0.9% NaCl, scraped into phosphate lysis buffer on ice, and 
sonicated for 8X with ultrasonicator. After centrifugation at 2000 g at 4oC for 5 min, 
the supernatants were used for phosphatase assay. Cell lysates (5 µl) were diluted 
in 20 µl phosphatase assay buffer at room temperature for 5 min. The reaction was 
terminated by adding 100 µl malachite green detection solution and 15 min later the 
absorbance at 630 nm was measured and corrected by subtracting the reading of 
the bank without lysates. 
MATERIALS & METHODS 
 
 
45 
 
2.7 Analysis of protein expression  
Western blotting (immunoblotting) is a rapid and sensitive assay for the detection 
and characterization of proteins that works by exploiting the specificity inherent in 
antigen-antibody recognition. It involves the solubilization and electrophoretic 
separation of proteins, glycoproteins, or lipopolysaccharides by SDS PAGE or urea-
PAGE, followed by quantitative transfer and irreversible binding to nitrocellulose, 
PVDF, or nylon. This technique has been useful in identifying specific antigens 
recognized by polyclonal or monoclonal antibodies, and is highly sensitive (1 ng of 
antigen can be detected). 
Materials 
Methanol Sigma-Aldrich, Steinheim, Germany 
Skim milk powder Carl Roth, Karlsruhe, Germany 
BSA endotoxin-free Sigma-Aldrich, Steinheim, Germany 
Calyculin A (CA) Santa Cruz Biotechnology, Heidelberg, Germany 
Okadaic acid (OA) Santa Cruz Biotechnology, Heidelberg, Germany 
Protease inhibitor cocktail (P1860) Sigma-Aldrich, Steinheim, Germany 
Compound C Calbiochem/EMD Biosciences, San Diego, USA 
BCA Protein Assay Kit Pierce, Rockford, USA 
Rainbow marker  Amersham Biosciences, Freiburg, Germany 
PVDF membrane Amersham Biosciences, Freiburg, Germany 
Hyperfilm Amersham Biosciences, Freiburg, Germany 
ECL substrate reagent  Amersham Biosciences, Freiburg, Germany 
Electrophoresis apparatus                
(Mini Protean II) 
BioRad Laboratory, Munich, Germany 
Power supply  BioRad Laboratory, Munich, Germany 
Sonorex RK 100 SH Bandelin, Berlin, Germany 
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2.7.1 Preparation of samples  
Whole cell lysates 
Cells were seeded in 9 cm plates (0.5 x 106) for 24 h, then the cells were starved 
using serum-free medium overnight, after that the cells were either left untreated or 
treated with C-KβBA for different time point, followed by activation of the cells by 1% 
FCS for 30 min. Cells were harvested by scraping in the medium on ice, collected by 
centrifugation, 400 x g at 4°C for 5 min. The pellet was washed in ice-cold PBS. After 
another centrifugation, the pellet was resuspended in lysis buffer (RIPA buffer) and 
stored on ice for 15 min, followed by 15 min sonication on ice. The solution was 
cleared by centrifugation (21,000 x g at 4°C for 5 min) and the protein solution 
transferred to fresh eppendorf tubes. The protein solution was diluted 1: 3 with 3x 
sample lyses buffer, boiled at 95°C for 5 min and stored at -20°C or used directly for 
electrophoresis.  
RIPA buffer: 
(Radio Immuno Precipitation Assay buffer): 
150 mM Sodium chloride 
1.0% NP-40 or Triton X-100 
0.5% Sodium deoxycholate 
0.1% Sodium dodecyl sulphate (SDS) 
 50 mM Tris-HCl, pH 8.0 
Add 1:100 protease and phosphatase 
inhibitors  
Sample lysis buffer (3X SLB): 
150 mM Tris-HCl (pH 7.0)  
12% SDS  
6% β-mercaptoethanol  
30% glycerol  
0.05% Coomassie Brilliant Blue 
 
 
Cytosolic (cytoplasmic) and nuclear extracts 
Cells were seeded in 9 cm Petri dishes (1x 106) for 24 h, then the cells were starved 
using serum-free medium overnight, after that the cells were either left untreated or 
treated with C-KβBA for 30 min, followed by activation of the cells by 1% FCS for 30 
min. Cells were harvested by scraping in the medium on ice, collected by 
centrifugation (400 x g at 4°C for 5 min) and resuspended in 150 µl of buffer A for 10 
min. Samples were centrifuged at 3000 x g at 4°C for 5 min to collect the 
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supernatants containing cytosolic proteins for determination of IκB-α by Western blot 
analysis. The pelleted nuclei were resuspended in 50 µl of buffer B. After 20 min at 
4°C, the samples were sonicated on ice for 10 min, then the lysates were centrifuged 
25,000 x g at 4°C for 5, and supernatants containing the nuclear proteins were 
transferred to new vials. Subsequently, nuclear extractions were analyzed by 
Western blot against NFκB-p65 protein and topoisomerase (Topo) I as control for 
loading. 
Buffer A 
10 mM HEPES (PH 7.9) 
1.5 mM MgCl 
10 mM KCl  
0.1% Igepal CA630 
0.5 mM DTT 
Buffer B 
10 mM HEPES (PH 7.9) 
1.5 mM MgCl 
0.42 mM NaCl 
0.5 mM DTT 
25% glycerol 
0.2 mM EDTA 
Add 1:100 protease and phosphatase inhibitors, and DTT freshly before 
using. 
2.7.2 Protein determination  
The method, developed by (Smith et al. 1985), is based on the bicinchoninic acid 
(BCA) reaction for the colorimetric detection and quantification of total protein. This 
method combines the well-known reduction of Cu++ to Cu+ by protein in an alkaline 
medium (the biuret reaction) with the highly sensitive and selective colorimetric 
detection of the cuprous cation (Cu+) using a reagent containing bicinchoninic acid. 
The purple-colored reaction product of this assay is formed by the chelation of two 
molecules of BCA with one cuprous ion. This water-soluble complex exhibits a 
strong absorbance at 562 nm. The protein contents of the lysates can, thus, be 
quantified by comparing the absorption with a calibration curve prepared with 
increasing concentrations of BSA in H2O. The measurements were performed in 
ELISA plates with an ELISA plate reader.  
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Protocol 
Cell lysates were diluted 1: 10 in H2O. 100 µl of BCA working solution was added to 
lysate solutions and 60 min were allotted for the color shift to develop. The plates 
were measured at 562 nm 
2.7.3  SDS-PAGE  
The protein samples described above were separated by denaturing SDS-
polyacrylamide gel electrophoresis. Sodium dodecyl sulfate (SDS) is anionic 
detergent that binds to the hydrophobic parts of the proteins and solubilizes them. 
Thereby, proteins lose secondary and tertiary structures and only retain their primary 
structure. SDS confers a high negative charge to the proteins proportional to the 
length of the amino acid chain, thus, covering any charges the proteins displayed 
themselves. In an electric field, the negatively charged proteins are drawn towards 
the anode, and they are separated solely on the basis of their size by the pores of 
the polyacrylamide gel. Further unfolding of the proteins is achieved by adding the 
reducing agent, dithiothreitol (DTT) or β-mercaptoethanol (BME), by which disulfide 
bonds inside the proteins are cleaved. 
The molecular weight is determined by comparison with molecular weight standard 
mixtures. 
Protocol 
All protein separations were carried out in discontinuous gel electrophoresis, where a 
stacking gel allows proteins to be concentrated in a line before they enter the 
separation gel (Table 4). The concentration of the separation gel was adjusted 
depending on the size of the protein to be detected (Table 5). Electrophoresis was 
carried out using a vertical apparatus Mini Protean II that allows two gels to be run in 
parallel. 
Samples with equal amounts of protein and the molecular weight marker were 
loaded into the slots of the prepared polyacrylamide gels. Electrophoresis was run at 
70 V for stacking and at 110 V for separation of the protein mixture. 
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Table 4. Composition of SDS-PAGE gels (16 ml end volume) 
Ingredients 
Stacking gel Separating Gel 
4% 10% 12% 15% 
3XGB 2.66 ml 5.31 ml 5.31 ml 5.31 ml 
AB 30% 1.06 ml 5.33 ml 6.40 ml 8.00 ml 
Glycerol 50% ------- 3.36 ml 3.36 ml 2.24 ml 
H2O 4.23 ml 1.86 ml 0.77 ml 0.35 ml 
1 % APS 50 µl 100 µl 100 µl 100 µl 
TEMED 8 µl 10 µl 10 µl 10 µl 
 
 
Table 5. Concentration of polyacrylamide used for the separation of proteins with 
different molecular weight 
 (Sambrook et al. 2001). 
Acrylamide concentration (%) Linear Range of Separation (kDa) 
5 57-212 
7.5 36-94 
10 20-80 
12 12-60 
15 10-43 
 
2.7.4  Western blotting and detection of proteins 
For detection of the protein of interest, the protein bands were transferred after 
electrophoresis onto blotting membranes, incubated with specific antibodies and 
visualized by chemiluminescence reagents.  
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Protocol 
Western blot was carried out by semi-dry blotting using a discontinuous buffer 
system. Polyvinylidene difluoride (PVDF) membranes were activated by soaking in 
methanol for 2 min followed by at least 15 min in blotting buffer with filter papers. The 
transfer stack consisted of 6 filter papers wetted in blotting buffer, followed by the 
membrane, the gel and finally 6 filter papers soaked in blotting buffer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Western immunoblotting technique and detection of the proteins of interest 
 
The transfer was performed on a Transblot SD semidry transfer cell. The transfer 
was performed at 1.5 mA /cm2 for 40-60 min depending on the size of the protein to 
be detected. After transfer, the membranes were blocked in 5% non-fat dry milk in 
TBS-T for 1 h at room temperature. Subsequently; the membranes were immersed 
in the respective antibody solution (Table 4) diluted in 5% non-fat dry milk in TBS-T 
overnight at 4° C. After three wash steps in TBS-T for 10 min each, the adequate 
secondary horseradish peroxidase-labeled antibody was applied for 45 min at room 
temperature. Development of the blot was carried out after three more washings 
(TBS-T, 10 min each) with the ECL Plus substrate solution. Thereafter, the 
membranes were exposed to X-ray film for the appropriate time period. For all 
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Western blots, actin was used as control for the quantification of the amounts of 
loaded protein. Western blot results are representative of at least three independent 
experiments. 
Table 6. Antibodies used for immunoblotting 
Antibody Company Cat.No. 
Species/Mol. 
Weight 
Dilution 
Actin Chemicon MAB1501 Mouse, 42 kDa 1:1000 in 5% milk 
Akt1 Cell Signaling 2967 Mouse, 60 kDa 1:1000 in 5% milk 
C-myc Santa Cruz sc-789 Rabbit, 67 kDa 1:500 in 5% BSA 
Cyclin D1 Santa Cruz sc-717 Rabbit, 36 kDa 1:1000 in 5% BSA 
eIF4E Santa Cruz P-2 (sc 9976) Mouse, 28 kDa 1:1000 in 5% BSA 
ERK1/2 Cell Signaling 9102 Rabbit, 42, 44 kDa 1:1000 5% BSA 
IκB-α Cell Signaling 9242 Rabbit, 39 kDa 1:1000 in 5% milk 
NF-κB p65 Epitomics 1546-1 Rabbit, 65 kDa 1:1000 in 5% milk 
p-70S6K Santa Cruz sc-8418 Mouse, 70 kDa 1:1000 in 5% BSA 
p-AktSer473 Upstate 5756 Rabbit, 60 kDa 1:1000 in 5% milk 
P-eIF4ESer209 Santa Cruz sc 12885 Mouse, 28 kDa 1:1000 5% BSA 
p-ERK Cell Signaling 9106 Mouse, 42, 44 kDa 1:2000 5% milk 
p-p70S6K Epitomics CO4159 Rabbit, 70 kDa 1:5000 in 5% BSA 
p-PDK Ser241 Cell Signaling 3061 Rabbit, 58, 68 kDa 1:1000 in 5% milk 
Topo I Santa Cruz sc-789 Rabbit, 100 kDa 1:1000 in 5% BSA 
α-tubulin 
Oncogene 
Research  
CP06 Mouse, 60 KDa 1:5000 in 5% milk 
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Solutions and Buffers for Immunoblotting 
30% Acrylamide solution (AB)  
30% acrylamide 
0.8% N-N´-methylenebisacrylamide 
100 ml H2O  
3x Gel buffer (GB) 
3 M Tris HCl (pH 8.45) 
0.3% SDS 
18.16 g Tris 
10 ml 5 N HCl 
50 ml H2O 
TBS (Tris-buffered saline)  
200 mM Tris-HCl 
1.37 M NaCl (PH 7.6) 
 
 
Blotting buffer 
192 mM glycine  
25 mM Tris (pH 8.3)  
10% or 20% methanol  
TBS-T 
TBS + 0.1% Tween 
 
Cathode buffer 
100 mM Tris (pH 8.25)  
100 mM Tricine  
0.1% SDS 
Phosphatase inhibitors (100X) 
125 mM NaF  
250 mM β-glycerophosphate 
25 mM Na3VO4 (sodium orthovanadate) 
Blocking buffer 
5% milk in TBS-T 
or 
5% BSA in TBS-T 
Anode buffer  
100 Tris-HCl (pH 8.9)    
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2.8 FKHR (FOXO1) ELISA 
Enzyme-linked immunosorbent assay (ELISA) was used to investigate the effect of 
C-KβBA on the activity of Forkhead box O1 (FOXO1). Forkhead box (FOX) 
consensus DNA sequence has been immobilized on 96-well plates. FKHR contained 
in nuclear extracts binds specifically to this DNA molecule, and is detected through 
the use of an antibody directed against FKHR. Addition of a secondary antibody 
conjugated to horseradish peroxidase (HRP) provides a sensitive colorimetric 
readout that is easily quantified by spectrophotometry. 
Materials 
TransAMTM FKHR (FOXO1) 
activity assay kit 
Active Motif, Rixensart, Belgium 
ELISA reader Dynatech MR 7000, Germany 
Protocol  
PC-3 cell (3 x 106) cultivated in F-12K medium for 24 h were treated with C-KβBA, 
KBA and AKT VIII inhibitor (positive control) for 3 h. FKHR (FOXO1) transcriptional 
activation was analyzed in isolated nuclear extracts from PC-3 using a commercially 
available transcription factor assay kit (TransAMTM FKHR (FOXO1) ) according to the 
manufacturer's instructions. 
2.9 Statistical analysis 
The results are expressed as the mean ± SEM. The significance was analyzed using 
the Newman-Keuls test for multigroup comparisons; p < 0.05 was considered 
significant. * p < 0.05, **p < 0.01. 
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3. RESULTS 
3.1 Synthesis of C-KβBA  
Starting from pure 11-keto-β-boswellic acid, we synthesized by means of a Steglich 
esterification reaction (Neises et al. 1978) a novel compound, which we identified by 
MS and NMR as 3-cinnamoyl-11-keto-β-boswellic acid (Figure 14). The compound 
was obtained as white small crystals upon precipitation with water from methanol. 
Upon control of sample purity by TLC, HPLC, MS and one and two dimensional 
NMR no contamination was detected. UV λmax = 266 nm (methanol); CI-MS: m/z = 
601 M+-H (calcd. for M+-H Peak C39H53O5: 601.38). Fragmentation of the novel 
compound showed characteristic fragments, m/z = 481 (loss of part from cinnamic 
acid), m/z = 453 (loss of carbonmonoxid), m/z = 409 (loss of carbondioxid) and two 
typical fragments for 11-keto-β-boswellic acid (m/z = 232 and 273 Da) (Pardhy et al. 
1978). The NMR analyses showed an intact connectivity of the triterpenoid and also 
the cinnamic acid fragment. The comparison with the educt (11-keto-β-boswellic 
acid) correlation indicated remarkable shifts in the A-ring, distinctive at position 3. 
The HMBC experiment revealed a long-range coupling between the proton at 
position 3 (δ = 5.46 ppm) and the carboxylic group (position 31, δ = 166.09 ppm) of 
the cinnamic acid ester. The MS results and the NMR A-ring shift suggested the 
shown structural connections, the HMBC long-range coupling verified the connection 
of the cinnamic acid compound with the triterpene at position 3 with a high yield. 
Based on the known conformational data (Belsner et al. 2003), the known dd 
multiplet (2,6 Hz) of the proton in position 3 (equatorial), and the pattern of proton 
coupling (positions 3, 2, 1), the conformation of the cinnamoyl derivative was 
established. 
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Figure 14. Structure, synthesis and mass-spectroscopy of C-KβBA 
A) Structure and numbering scheme with the determining HMBC correlation of C-KβBA. B) 
Scheme for C-KβBA synthesis. C) Mass-spectroscopy was performed using a Finnigan MAT 
electrospray ionisation mode.  
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Table 7. NMR of C-KβBA 
 
1
H-NMR and 
13
C-NMR assignments (δ in ppm) for 3-cinnamoyl-11-keto-β-boswellic acid. 
(100 MHz 
13
C NMR, 400 MHz 
1
H NMR, CDCL3).  
 δ
13
C (ppm) M. δ
1
H (ppm) M. 
1 34.76 CH2 1.35 m 
   2.60 m 
2 23.66 CH2 1.72 m 
   2.31  
3 73.17 CH 5.46 d 
4 46.76 C   
5 50.66 CH 1.51 m 
6 18.80 CH2 1.74 m 
   1.89 m 
7 32.95 CH2 1.74 m 
   1.51 m 
8 45.1 C   
9 60.43 CH 2.47 s 
10 37.46 C   
11 199.17 C   
12 130.55 CH 5.57 s 
13 164.82 C   
14 43.78 C   
15 27.26 CH2 1.24 m 
   1.92 m 
16 27.56 CH2 1.04 m 
   2.11 m 
17 33.98 C   
18 59.05 CH 1.52 m 
19 39.29 CH 1.49 m 
20 39.34 CH 0.94 m 
21 30.93 CH2 1.45 m 
   1.30 m 
22 40.93 CH2 1.49 m 
   1.34 m 
23 23.96 CH2 1.30 s 
24 181.7   s 
25 13.25 CH3 1.18 s 
26 18.43 CH3 1.22 s 
27 20.53 CH3 1.39 s 
28 28.87 CH3 0.83 s 
29 17.44 CH3 0.80 d 
30 21.14 CH3 0.94 s 
31 166.09 C   
32 118.45 CH 6.48 d 
33 144.9 CH 7.70 d 
34 134.44 C   
35 128.09 CH 7.54 m 
35’  CH 7.54 m 
36 128.86 CH 7.39 m 
36’  CH 7.39 m 
37 130.27 CH 7.39 m 
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3.2 Antiproliferative effect of C-KβBA 
The antiproliferative effect of C-KβBA on PC-3 cells was measured by using an XTT 
assay. The data revealed that treatment of PC-3 cells with C-KβBA for 24 and 48 h 
exerts a concentration- and time-dependent inhibition of the proliferation of PC-3 
cells with an IC50 value of 4.2 and 3.8 µM, respectively (Figure 15). Our data showed 
that C-KβBA is more potent than the parent compounds (cinnamic acid and KBA), 
also more potent than other derivatives, such as cinnamic acid methyl ester and 
AKβBA. 
 
Figure 15. Antiproliferative effect of C-KβBA and the parent compounds on PC-3 cells 
Antiproliferative effect of C-KβBA and the parent compounds on PC-3 cells were measured 
by an XTT assay. PC-3 cells were treated with above-mentioned compounds for 24 and 48 h. 
The amount of cells in control samples treated with DMSO solvent (0.5%) was set to 100%. 
Data are mean ± SEM from three independent experiments. 
 
Furthermore, C-KβBA has a remarkable cytotoxic profile, not only on PC-3 cell line, 
but also on LNCaP and DU 145 prostate cancer cell lines (Figure 16). 
Interestingly, C-KβBA showed a relatively selective efficacy against prostate cancer 
cells (PC-3 cell line) compared to normal prostate epithelial cell (RWPE-1 cell line) 
with IC50 values of 3.6 µM and 10.8 µM, respectively (Figure 17). 
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Figure 16. Antiproliferative effect of C-KβBA on different cell lines 
Antiproliferative effect of C-KβBA on different prostate cancer cell lines was measured by an 
XTT assay. The indicated cell lines were treated with C-KβBA for 24 and 48 h. The amount of 
cells in control samples treated with DMSO solvent (0.5%) was set to 100%. Data are mean ± 
SEM from three independent experiments.  
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Figure 17. C-KβBA shows relatively selective antiproliferative effects against tumor cells 
Antiproliferative effect of C-KβBA on the PC-3 cell line (prostate cancer) and the RWPE-1 cell 
line (normal prostate epithelial cells) was measured by an XTT assay. A) Indicated cell lines 
were treated with C-KβBA for 48 h. The amount of cells in control samples treated with 
DMSO solvent (0.5%) was set to 100%. B) The results are expressed as IC50 value from both 
cell lines. Data are mean ± SEM from three independent experiments. Statistical analysis was 
performed using the Newman-Keuls test, *p < 0.05.  
To determine whether the PC-3 cell line is able to recover from the antiproliferative 
effect of C-KβBA or not, we treated PC-3 cells with C-KβBA for 24 h, then we 
changed the medium to C-KβBA-free medium for 6 days. The cell viability was 
measured by a clonogenic survival assay. The results demonstrate that the PC-3 
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cells were not able to recover from a single treatment with C-KβBA at a 
concentration as low as 1 µM. At the same time, the long time treatment with C-
KβBA induced a stronger anticlonogenic effect than CCI-779, an inhibitor of mTOR 
signaling that used in clinical trials (Figure 18). 
Figure 18. The antiproliferative effect of C-KβBA on PC-3 cells is irreversible 
A) The antiproliferative effect of C-KβBA on the PC-3 cell line for longer time was measured 
by an XTT assay. PC-3 cells were treated with the indicated compounds for 24 h, then the 
cells were cultivated in compounds-free medium for 6 day. Photos had been taken of the 
plates, then the colonies were solubilized in 33% acetic acid, followed by spectrophotometric 
analysis (clonogenic survival assay). B) The results are expressed as mean ± SEM of three 
independent experiments. Statistical analysis was performed using the Newman-Keuls test, 
**p < 0.01. 
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3.3 C-KβBA induces cell cycle arrest  
Because cell proliferation and growth controlled by the progression of the cells 
through the well-defined stages of the cell cycle, we next determined the effects of 
C-KβBA on the cell cycle progression of PC-3 cells. We analyzed the cell cycle 
distribution by flow cytometry using propidium iodide DNA staining. The flow 
cytometric analyses of the DNA profile showed that the treatment of PC-3 cells with 
various concentrations of C-KβBA (1 and 3 µM) for 24 and 48 h effectively arrested 
PC-3 cells in the G1 phase of the cell cycle (Figure 19). 
 
Figure 19. C-KβBA induces cell cycle arrest  
The effects of C-KβBA on the cell cycle distribution was measured by flow cytometry (FACS). 
PC-3 cells were treated with various concentrations of C-KβBA for 24 h (A) and 48 h (B). The 
cells were fixed in ethanol, subsequently stained with propidium iodide and analyzed by 
FACS. Cell cycle analysis was performed and quantified by using ModFit software (Aa and 
Ba). The data represent three independent experiments. Statistical analysis was performed 
using Newman-Keuls test, **p < 0.01. 
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C-KβBA treatment significantly increased the proportion of cells in the G1 phase 
(Figure 19, Aa and Ba). This is an interesting finding because PC-3 cells express 
mutant p53 alleles, losing the function of p53. Therefore, it appears that C-KβBA is 
able to arrest cells in the G0/G1 phase and inhibit the proliferation of PC-3 cells in a 
p53-independent manner. 
3.4 C-KβBA triggers apoptosis in vitro  
The next step was performed to evaluate which type of cell death occurred in PC-3 
cells upon C-KβBA exposure. We investigated the proapoptotic activity of C-KβBA by 
measuring several apoptotic parameters, such as the expression of 
phosphatidylserine on the cell surface, caspase activation and the definitive sign of 
apoptosis, DNA laddering. 
3.4.1 C-KβBA induces phosphatidylserine expression on the cell surface  
During apoptosis, phosphatidylserine physiologically located at the inner membrane 
leaflet is flipped to the cell surface, where it serves as an "engulfing" signal for 
neighboring cells (Vermes et al. 1995). Treatment of PC-3 cells with 3, 5 or 10 µM C-
KβBA for 24 h triggered expression of phosphatidylserine on the outer membrane 
leaflet, as determined by FITC-labelled annexin V and propidium iodide staining, 
followed by flow cytometric analysis (Figure 20). The result revealed that C-KβBA 
exerts expression of phosphatidylserine in PC-3 cells in a concentration-dependent 
manner.  
3.4.2 C-KβBA induces caspase-3 activation  
Caspases are crucial mediators of the programmed cell death (apoptosis). Among 
them, caspase-3 is a crucial effector caspase, catalyzing the specific cleavage of 
many key cellular proteins. Caspase-3 is essentail for some typical hallmarks of 
apoptosis and is indispensable for apoptotic chromatin condensation and DNA 
fragmentation (Porter et al. 1999). We show here that treatment of PC-3 cells for 24 
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h with C-KβBA induces caspase-3 activation in a concentration-dependant manner 
(Figure 21).  
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Figure 20. C-KβBA induces phosphatidylserine expression on the cell surface 
A) PC-3 cells were treated C-KβBA (3, 5, and 10 µM) for 24 h, harvested, stained with 
annexin V/propidium iodide and analyzed by flow cytometry. Untreated control cells were also 
included in the analysis. Annexin V-FITC signals are recorded in FL1-H and propidium iodide 
in FL2-H. Cells in the bottom left quadrant (annexin V-negative, propidium iodide-negative) 
are viable, whereas cells in the lower right quadrant (annexin V-positive, propidium iodide-
negative) are in the early stages of apoptosis, and the cells in the top right quadrant (annexin 
V-positive, propidium iodide-positive) are in later stages of apoptosis and necrosis. B) 
Apoptosis analysis was performed and quantified by using ModFit software. Data are mean ± 
SEM from three experiments. Statistical analysis was performed using the Newman-Keuls 
test, * p < 0.05, **p < 0.01. 
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Figure 21. C-KβBA induces caspase-3 activation 
Capase-3 activity was measured by proteolytic cleavage of the fluorogenic substrate Z-
DEVD-R110. Cells were treated for 24 h with the corresponding concentrations of C-KβBA or 
vehicle as control. The caspase activity was measured fluorometrically with an excitation 
wavelength of 496 nm and an emission wavelength of 520 nm. Data are mean ± SEM from 
three experiments. Statistical analysis was performed using the Newman-Keuls test,            
**p < 0.01. 
3.4.3 C-KβBA induces DNA laddering  
A biochemical hallmark of apoptosis is the cleavage of chromosomal DNA into 
oligonucleosome-sized fragments by endonuclease activation triggered by caspase 
3, a process called DNA fragmentation or DNA laddering. Our result revealed that 
treatment of PC-3 cells with C-KβBA (5 µM) for 96 h led to a typical DNA laddering 
pattern (Figure 22). 
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Figure 22. C-KβBA induces DNA laddering 
PC-3 cells treated with C-KβBA (5 µM) for 96 h. The cell lysates were analyzed for DNA 
fragmentation by agarose gel electrophoresis. The data shown are representative for three 
independent experiments. 
3.5 C-KβBA inhibits growth, proliferation, and triggers apoptosis in vivo 
To verify the proapoptotic and antiproliferative activity of C-KβBA in vivo, we next 
xenotransplanted PC-3 cells onto the chorioallantoic membranes (CAM) of fertilized 
chicken eggs. Immunohistochemical analysis of the tumor sections for human 
proliferation antigen Ki-67 (proliferation marker) revealed that C-KβBA had a 
concentration-dependent inhibitory effect on tumor proliferation.  
By using the TUNEL technique for in situ detection of apoptosis, we showed that C-
KβBA triggers apoptosis also in vivo (Figure 23). These data show that C-KβBA 
inhibits the growth of established PC-3 xenografts in vivo even more efficient than in 
vitro.  
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Figure 23. C-KβBA inhibits growth, proliferation, and triggers apoptosis in vivo 
 PC-3 cells (1 × 10
6
) were grafted onto the chorioallantoic membranes of fertilized chicken 
eggs. After 2 days, the tumors were topically treated either with 20 µl of C-KβBA or DMSO 
alone (control) for 4 days before termination of the experiment. Tumor sections were stained 
against Ki-67 (proliferation marker, brown nuclear stain) and TUNEL (apoptosis marker, dark 
brown stain). Data shown are representative of 3 eggs each.  
3.6 C-KβBA inhibits the mTOR signaling pathway 
To better understand the mechanisms and pathways involved in the induction of 
apoptosis by C-KβBA, we have examined the effects of C-KβBA against several 
kinases known to be constitutively active in PC-3 cells. Previously we have shown 
that the acetylated form of KBA (AKβBA) induces apoptosis by downregulation of 
NF-κB signaling pathway (Syrovets et al. 2005). To figure out the relation between 
C-KβBA and NF-κB signaling pathway, overnight-starved PC-3 cells incubated with 
C-KβBA for 30 min followed by stimulation for 30 min with 1% FCS. Gel 
electrophoresis of cytosolic and nuclear extracts stained for IκB-α (NF-κB-inhibitory 
protein) and p65 (the major transcription activating NF-κB family member) revealed 
that C-KβBA did not altered the level of both proteins (IκB-α and p65). Also the 
Western immunoblot for IκB-α of the whole cell lysates from overnight starved PC-3 
cells incubated with C-KβBA for 30 min followed by 30 min FCS 1% incubation 
indicated that C-KβBA did not altered the level of IκB-α protein (Figure 24). These 
results exclude the involvement of the NF-κB signaling pathway in the induction of 
apoptosis by C-KβBA. 
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Figure 24. Effect of C-KβBA on the NF-κB signaling pathway 
Whole cell lysates, cytosolic and nuclear fractions of PC-3 cells, starved overnight, treated 
with C-KβBA for 30 min and stimulated for 30 min with FCS, were used for Western blotting. 
Control cells were treated either with DMSO (0.5%) or CCI-779 or rapamycin used as positive 
controls. Data represent three independent experiments. 
 
Further studies revealed that within 60 min, C-KβBA induced a rapid downregulation 
of the phosphorylation of p70S6K kinase in PC-3 cells (Figure 25). The p70S6 
kinase 1 (p70S6K) is the best-characterized effector of mTOR (Ali et al. 2005). It has 
been shown that p70S6K and phospho-p70S6K are expressed at a higher level in 
prostate cancer cells compared to normal cells (Kremer et al. 2006). Inhibition of 
mTOR exerts hypophosphorylation of p70S6K in prostate cancer in vitro and vivo 
(Wu et al. 2005; Bianchini et al. 2008). 
 
 
IκB-α
Actin
p65
Topo I
IκB-α
Actin
0.3    1      3        
C-KßBA (µM)
Lysate
Lysate
NE
NE
Cytosol
Cytosol
RESULTS 
 
 
67 
 
To determine the inhibitory effect of C-KβBA on mTOR signaling pathway, we 
examined the phosphorylation of p70S6K and eIF4E as prime candidates for mTOR 
downstream targets. PC-3 cells treated with C-KβBA (0.3, 1, 3 µM) for different time 
periods showed that C-KβBA inhibits the phosphorylation of p70S6K and eIF4E in 
concentration- and time-dependant manner without altering the total p70S6K protein 
(Figure 25).  
The activity of mTORC1 and mTORC2 were further determined by monitoring the 
phosphorylation status of p70S6K at Thr389 and Akt at Ser473, respectively 
(Thoreen et al. 2009) (Figure 25). 
Interestingly, C-KβBA also downregulated the phosphorylation of p70S6K in vivo, in 
the CAM assay. Moreover, C-KβBA was more effective in vivo than in vitro (Figure 
26). 
Hypophosphorylated 4E-BPs binds with high affinity to eIF4E, prevents association 
of eIF4E with EIF4G and formation of the eIF4E initiation complex, and, thereby, 
inhibits cap-dependent translation of mRNA. mTOR phosphorylates the eIF4E-
binding protein (4E-BPs) and leads to dissociation of eIF4E (Hay et al. 2004). 
Inhibition of mTOR exerts upregulation of p-eIF4E in the prostate cancer cell line PC-
3 (Bianchini et al. 2008) and in lung cancer cells (Chen et al. 2009). Here we show 
that C-KβBA upregulates eIF4E phosphorylation in the PC-3 cell line (Figure 25).  
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Figure 25. C-KβBA inhibits the mTOR signaling pathway in vitro 
Whole cell lysates from PC-3 cells, starved overnight, treated with C-KβBA in the indicated 
concentration and stimulated for 30 min with 1% FCS, were used for Western blotting. Data 
shown are representative of three independent experiments. 
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Figure 26. C-KβBA inhibits the mTOR signaling pathway in vivo 
PC-3 cells (1 × 10
6
) were grafted onto the chorioallantoic membranes of fertilized chicken 
eggs. After 2 days, the tumors were topically treated either with 20 µl of C-KβBA or DMSO 
alone (0.5%, control) for 4 days before termination of the experiment. The tumor sections 
were stained against p-p70S6K (AEC, red stain). Data shown are representative of 3 eggs 
each. 
Activation of eIF4E is elevated significantly with progression of human and 
experimental prostate cancer, and significantly related to reduce patient survival. 
Reduction of eIF4E in prostate cancer cells elicits apoptosis in a cell cycle phase-
independent manner (Graff et al. 2009). Here we show that C-KβBA, although it 
upregulated the eIF4E phosphorylation, concomitantly reduced eIF4E expression in 
prostate cancer cells (Figure 25). 
The proto-oncogene cyclin D1 is an important regulator of G1 to S-phase transition 
and an important cofactor for several transcription factors in numerous cell types 
(Alao et al. 2006). Inhibition of the mTOR signaling pathway induced down-regulation 
of cyclin D1 leading to cell cycle arrest at G1 phase (Xu et al. 2006; Averous et al. 
2008). Treatment of prostate cancer cell lines with C-KβBA for 8, 12 and 24 h 
downregulated cyclin D1 and mediated cell cycle arrest at G1 phase as well (Figure 
25). 
PC-3 is a PTEN-null cell line. Loss of PTEN in this cell line is associated with a 
hyperactivated PI3K/Akt/TSC/mTORC1 pathway. To clarify that C-KβBA targets the 
mTOR signaling pathway, we measured the cytotoxicity by the XTT assay in PTEN 
positive PC-3 cells exposed to different concentrations of C-KβBA for 48 h. 
Compared to PTEN null PC-3 cells, we found that PTEN positive PC-3 cells are 
insensitive to C-KβBA. This confirmed our hypothesis that C-KβBA targets the 
mTOR signaling pathway (Figure 27). 
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Figure 27. C-KβBA shows selective antiproliferative effects against the PTEN null cell line 
Antiproliferative effect of C-KβBA on PC-3 cell line and PC-3 PTEN cell line was measured by 
the XTT assay. Indicated cells lines were treated with C-KβBA for 48 h. The amount of cells in 
control samples treated with DMSO solvent (0.5%) was set to 100%. Data are mean ± SEM 
from three independent experiments. 
Taken together, inhibition of p70S6K phosphorylation, upregulation of eIF4E 
phosphorylation, downregulation of cyclin D1 and eIF4E expression, no alteration in 
AKT and ERK phosphorylation, and relative resistance of PTEN positive PC-3 to 
treatment with C-KβBA confirmed our hypothesis that C-KβBA inhibits the mTORC1 
signaling pathway. 
3.7 C-KβBA inhibits the mTOR signaling pathway independent from upstream 
kinases 
The mTOR signaling is activated in response to growth factors and nutrients. Under 
such conditions, PI3K/Akt signaling will be activated and will regulate mTOR 
signaling. Activated Akt phosphorylates TSC2 inducing Rheb GTPase inactivation, 
which associates with and directly activates mTORC1. It is known that PDK1 
phosphorylates and activates Akt at T309 and p70S6K at Thr229 (Meric-Bernstam 
and Gonzalez-Angulo 2009). Thus, C-KβBA could inhibit mTOR signaling by down-
regulation of upstream kinases.  
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To determine whether C-KβBA would affect the activity of Akt and PDK1 or not, PC-3 
cells were treated with and without C-KβBA for 30 min, then stimulated with 1% FCS 
for 30 min, followed by Western blot analysis of p-PDK1, p-Akt-Ser473, p-Akt-Thr308 
and Akt. Our results revealed that treatment of PC-3 cells with C-KβBA did not affect 
the phosphorylation of both upstream kinases, PDK1 and Akt (Figure 28).    
Moreover, we tested the effect of C-KβBA on the downstream targets of Akt (GSK-
3β and FOXO) to ensure that there is no inhibition of Akt activity in cells treated with 
C-KβBA. Glycogen synthase kinase-3β (GSK-3β) is a serine threonine kinase 
involved in metabolism, neurodegeneration and cancer progression. It has been 
shown that GSK-3β regulates apoptosis in response to various stimuli. GSK-3β is 
phosphorylated by Akt at Ser9. Therefore, inhibition of Akt leads to downregulation of 
GSK-3β-Ser9 phosphorylation. Western blot analysis of GSK-3β-Ser9 showed that 
C-KβBA did not alter the phosphorylation status of GSK-3β on Ser9 (Figure 28).  
Mammalian forkhead members of the class O (FOXO) are transcription factors 
including FOXO1, FOXO3a, and FOXO4. FOXO are key regulators of growth, 
metabolism, life span, and stress resistance. Akt phosphorylates FOXO leading to 
FOXO cytoplasmic retention and transcriptional inactivation. Inhibition of Akt 
activates FOXO transcription factors. ELISA assay for FOXO activity revealed that 
C-KβBA did not induce activation of FOXO transcription. The experiments showed 
that there is no relation between Akt and mTOR inhibition induced by C-KβBA 
(Figure 28).   
This indicated that C-KβBA does not affect the activity of PDK1 or Akt, and induces 
inhibition of mTOR signaling independently of PDK1 and Akt signaling. 
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Figure 28. C-KβBA inhibits the mTOR signaling pathway independent from the upstream 
kinase Akt 
A) Whole cell lysates from PC-3 cells, starved overnight, treated with C-KβBA for 30 min and 
activated for 30 min with 1% FCS, were used for Western immunoblotting. Data represent 
three independent experiments. B) The graphic presentation shows the effects of C-KβBA on 
FOXO1 activity. PC-3 cells were incubated with C-KβBA, KBA and the Akt inhibitor VIII (1 µM, 
positive control) for 3 h. FKHR (FOXO1) transcriptional activation was analyzed in isolated 
nuclear extracts from PC-3 cells using a commercially available transcription factor assay kit 
(TransAM
TM
 FKHR (FOXO1)) according to the manufacturer's instructions. 
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3.8 C-KβBA inhibits the mTOR signaling pathway independent from the 
LKB1-AMPK signaling pathway 
The AMPK-TSC network is negative upstream regulator of mTOR. In the response to 
low energy level or high AMP level, AMP kinase (AMPK) is phosphorylated by the 
liver Kinase B1 (LKB1) and activated; this leads to activation of TSC2 and inhibition 
of mTOR signaling (Meric-Bernstam et al. 2009). Therefore, we hypothesized that C-
KβBA might inhibit mTOR signaling by direct activation of LKB1-AMPK signaling 
pathway.  
To clarify, whether activation of LKB1 is involved in the C-KβBA-mediated inhibition 
of mTOR signaling, MDA-MB-231 cells, which do not express LKB1 mRNA or protein 
(Shen et al. 2002), were treated with C-KβBA at different concentration for 24 and 48 
h, followed by XTT assay. The results showed that the lack of LKB1 did not rescue 
MDA-MB-231 cell line from C-KβBA-induced cytotoxicity (Figure 29).  
In the next step, PC-3 cells treated with C-KβBA alone or with AMPK inhibitor 
(compound C) (Figure 29). The results reveal that pretreatment of the cells with 
compound C has no effect on C-KβBA-mediated inhibition of mTOR signaling 
(Figure 29).  
Together, this data demonstrated that C-KβBA inhibits mTOR signaling independent 
of the LKB1-AMPK signaling pathway. 
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Figure 29. C-KβBA inhibits the mTOR signaling pathway independent from the LKB1-AMPK          
signaling pathway 
A) PC-3 cells were treated for 24 h and 48 h with C-KβBA and the cytotoxicity was 
measured with XTT assay. B) Lysates from whole PC-3 cells, starved overnight, treated 
with 3 µM C-KβBA alone or with 1 µM AMPK inhibitor (compound C) for 30 min, followed 
by stimulation for 30 min with 1% FCS, were used for Western blotting. Data are mean ± 
SEM from three independent experiments. 
3.9 C-KβBA inhibits the mTOR signaling pathway independent from the TSC 
complex 
TSC2 is a negatively regulator for mTORC1. Multiple signaling cascades converge 
on TSC2, leading to its phosphorylation and inactivation. TSC2 is phosphorylated by 
multiple kinases, including Akt, ERK, RSK1 (a kinase downstream of ERK) and 
AMPK (Bai et al. 2009). In previous experiments, we showed that C-KβBA did not 
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affect the activity of Akt or AMPK signaling. At the same time, ERK phosphorylation 
was undetectable under the conditions tested (Figure 25). That indicates that C-
KβBA could target the TSC complex to inhibit mTORC1 signaling.  
To elucidate whether there is any relation between the mTOR inhibition and the TSC 
complex activation, we incubated C-KβBA with two mouse embryonic fibroblast cell 
lines, either expressing wild type TCS or deficient in TCS (MEFs TSC+/+ and MEFs 
TSC-/-) for 48 h (Figure 30). The results revealed that knockout of TSC did not rescue 
the cells from the C-KβBA-mediated apoptosis. This indicates that C-KβBA inhibits 
mTOR signaling pathway independent from the TSC complex. 
 
Figure 30. C-KβBA inhibits the mTOR signaling pathway independent from the TSC complex. 
Antiproliferative effect of C-KβBA on MEFs cell lines (TSC
-/-
 and TSC
+/+
) was measured by 
the XTT assay. The indicated cell lines were treated with C-KβBA for 48 h. The amount of 
cells in the control samples treated with DMSO solvent (0.5%) was set to 100%. Data are 
mean ± SEM from three independent experiments.  
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3.10  C-KβBA inhibits the mTOR signaling pathway independent from PP2A 
phosphatase activation 
Protein phosphatase 2A (PP2A) is a trimeric complex consisting of a catalytic 
subunit (C), and the regulatory subunits A and B. PP2A controls the activity of 
p70S6K and 4E-BPs.  
 
To explore the role of protein phosphatases in the C-KβBA-mediated inhibition of 
mTOR signaling, PC-3 cells were pretreated with the phosphatase inhibitors, 
calyculin A (a potent protein serine/threonine phosphatase inhibitor that inhibits both 
PP1 and PP2A) and okadaic acid (a potent PP2A inhibitor) for 20 min. Then the cells 
treated with or without C-KβBA, for 30 min followed by 30 min activation with 1% 
FCS. The cell lysates analyzed by Western immunoblotting (Figure 31). The results 
showed that calyculin A partially reversed the C-KβBA-mediated inhibitory effect on 
p70S6K phosphorylation, while okadaic acid had little effect on p70S6K 
phosphorylation in PC-3 cells. 
Next, we evaluated the effect of C-KβBA on the PP2A activity. PC-3 cells pretreated 
with calyculin A for 20 min, and then treated with or without C-KβBA for 30 min, 
followed by 30 min activation with 1% FCS. The activity of the protein phosphatase 
in the cells treated with C-KβBA determined by malachite green phosphatase assay 
(Figure 31). This data showed that C-KβBA did not affect the activity of PP2A. 
In these two experiments, treatment of PC-3 cells with C-KβBA had no effect on 
PP2A phosphatase activity. This revealed that C-KβBA inhibits the mTOR signaling 
pathway independent from PP2A activation. 
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Figure 31. C-KβBA inhibits the mTOR signaling pathway independent from PP2A activation 
A) Whole cell lysates from PC-3 cells, starved overnight, treated with 10 µM C-KβBA alone or 
with the indicated inhibitors for 30 min with stimulation for 30 min with 1% FCS, were used for 
Western immunoblotting using the indicated antibodies. D) The cells were pretreated with or 
without calyculin A (100 nM) for 20 min then incubated with different concentrations of C-
KβBA for 30 min. The cells were harvested in phosphatase assay buffer and PP2A activities 
in lysates were determined as described in Material and Methods. Data are mean ± SEM from 
three independent experiments .
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4. DISCUSSION 
Programmed cell death (apoptosis) is a conserved pathway that is essential for 
development and tissue homoeostasis. Tissue homeostasis is the critical balance 
between cell proliferation and cell death (apoptosis). Disruption of this subtle 
equilibrium can lead to the onset of various pathological disorders including cancer. 
Defects in the apoptotic process have also been implicated in the pathogenesis of 
autoimmune diseases, such as type 1 diabetes (Sun et al. 2005; De Franco et al. 
2007). Besides, it is involved in the pathogenesis of inflammatory bowel diseases, 
inflammatory allergic disorders (Druilhe et al. 2000; Duncan et al. 2003; Mudter et al. 
2007; Tumes et al. 2008), and most ocular diseases (Tempestini et al. 2003). In 
addition, defective apoptosis has been implicated in the resistance to many 
chemotherapeutic drugs (Ikuta et al. 2005). In light of these findings, induction of 
apoptosis could be of great therapeutic interest for the treatment of a variety of 
diseases. 
Our lab has previously shown that the pentacyclic triterpenoid acetyl-11-keto-β-
boswellic acid (AKβBA) induces apoptosis in prostate cancer cell lines in vitro and in 
vivo (Syrovets et al. 2005). In comparison to AKβBA, its deacetylated derivative, 11-
keto-β-boswellic acid (KBA), showed a decreased activity, pointing to the importance 
of the acetyl group at carbon number 3 of ring A. The aim of the present study was to 
modify this position in order to obtain a new derivative of KBA with enhanced 
proapoptotic activitiy. In our attempts to modify the substituent at carbon number 3, 
we have linked cinnamic acid to the hydroxyl group at carbon 3 of ring A of KBA, 
thereby creating the end product 3-cinnamoyl-11-keto-β-boswellic acid (C-KβBA). 
Here we show that C-KβBA induced a concentration- and time-dependent inhibition 
of the proliferation of different cell lines including the prostate cancer cell lines PC-3, 
LNCaP, DU 145, and the mammary carcinoma cell line MDA-MB-231. Interestingly, 
C-KβBA was more potent than CCI-779, a mTOR inhibitor that is currently being 
evaluated in clinical trials. 
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Importantly, C-KβBA showed a preferential efficacy against prostate cancer cells, i.e. 
the PC-3 cell line harboring defects in the apoptosis pathway, compared to normal 
prostate epithelial cells, i.e. the RWPE-1 cell line, suggesting specificity of C-KβBA 
against the cells with defects in the apoptosis pathway. Since resistance to 
chemotherapy usually arises with time, we treated PC-3 cell line with C-KβBA only 
once, followed by incubation in medium free of C-KβBA for 6 day. These 
experiments revealed that already a single application of C-KβBA has a profound 
cytotoxic effect on PC-3 cells showing that PC-3 cells are not able to recover from 
the C-KβBA-mediated cytotoxicity, even when the cells kept in C-KβBA-free medium 
for 6 days.  
It could further be demonstrated that C-KβBA induced apoptosis not only in vitro but 
also in vivo, suggesting that C-KβBA could be used for the treatment of diseases 
associated with defective apoptosis pathways. To elucidate the type of cell death 
triggered by C-KβBA, several apoptotic parameters, such as expression of 
phosphatidylserine on the cell surface, caspase activation, and DNA laddering were 
investigated.  
Caspase activation is one of the best-known biochemical markers indicating the 
induction of apoptosis. Caspases belong to the family of cysteine-aspartic acid-
directed proteases that play essential roles in the regulation of apoptosis. Caspases 
are widely expressed as inactive proenzymes, and once procaspases become 
activated, they trigger initiation of the protease cascade. Some procaspases can also 
aggregate and autoactivate. This proteolytic cascade, in which one caspase can 
activate other caspases, amplifies the apoptotic signaling pathway and thus leads to 
rapid cell death (Elmore 2007). Among them, caspase 3 is a frequently activated 
death protease, catalyzing the specific cleavage of many key cellular proteins. The 
effector caspase 3 is also required for some typical hallmarks of apoptosis such as 
apoptotic chromatin condensation and DNA fragmentation (Porter et al. 1999). 
Twenty-four h exposure of PC-3 cells to C-KβBA in concentrations as low as 1 µM 
C-KβBA induced already significant activation of caspase-3. This is consistent with 
the profound antiproliferative effect of C-KβBA on prostate cancer cells at this low 
concentration as verified for example by its anticlonogenic effect. Together, these 
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data unambiguously demonstrated that C-KβBA induced apoptotic cell death in 
prostate cancer cell lines.  
The tumor suppressor gene PTEN (phosphatase and tensin homologue) is a 
plasma-membrane lipid phosphatase. PTEN is mutated in multiple advanced 
cancers and is also associated with cancer-susceptibility conditions such as Cowden 
syndrome (Inoki et al. 2005; Cully et al. 2006). PTEN mutation is frequently 
entangled with human prostate carcinoma progression (Huang et al. 2001) 
suggesting a crucial role of PTEN in the context of this disorder. Consistently, loss of 
PTEN expression is associated with tumorgenesis and metastasis. Indeed, the 
treatment-resistant PC-3 cells are a PTEN-null cell line. Loss of PTEN in this cell line 
is biochemically associated with a hyperactivated PI3K/Akt/TSC/mTORC1 pathway 
(Cantley et al. 1999) raising the interesting question whether this pathway might be 
targeted by C-KβBA. 
The mammalian target of rapamycin (mTOR) acts as a central regulator of ribosome 
biogenesis, protein synthesis, cell growth, cell survival and cytoskeletal organization. 
The dysregulation of the mTOR signaling pathway is a hallmark for many diseases 
including cancer. It has been reported that the mTOR signaling pathway is 
associated with many neurological disorders (i.e. mental retardation syndromes, 
autism spectrum disorder, Alzheimer´s, Huntington’s and Parkinson’s disease) 
(Mizushima 2005; Santini et al. 2009; Hoeffer et al. 2010), and also with cardiac 
hypertrophy and polycystic kidney disease (Inoki et al. 2005; Boletta 2009). It also 
plays an important role in metabolic disorders including obesity, type 2 diabetes, and 
non-alcoholic fatty liver disease (Pacheco et al. 2008; Laplante et al. 2009). 
Mutations in LKB1, RasGAP (Ras GTPase-activating protein), TSC1, TSC2 and 
PTEN trigger development, e.g. of the Peutz-Jeghers syndrome, neurofibromatosis 
type I, and tuberous sclerosis syndrome, to name a few (Inoki et al. 2005).  
Recent studies revealed that the mTOR signaling pathway links diet-induced obesity 
with vascular senescence and cardiovascular diseases (Wang et al. 2009). In 
addition, the mTOR signaling pathway has been implicated in the resistance of tumor 
cells to many anticancer drugs including retinoic acid, vincristine and trastuzumab 
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(Jiang et al. 2008). Moreover, it has been shown that inhibition of the mTOR 
signaling pathway extends the lifespan in invertebrates (i.e. yeast and nematodes) 
as well as in mammalians species (i.e. mice) (Harrison et al. 2009). Thus, the mTOR 
signaling pathway apparently represents a key element that controls many diseases. 
Therefore, many efforts have been devoted to the identification of new mTOR 
inhibitors for cancer therapy. The immunosuppressive macrolide rapamycin is 
considered as the classical mTOR inhibitor. Many mTOR inhibitors are now in 
clinical trials, such as CCI-779 and deforolimus (Witzig et al. 2005; Rizzieri et al. 
2008).  
To enlighten the molecular mechanism underlying the cell death induced by             
C-KβBA, we investigated a variety of kinase-related signaling pathways in PC-3 
cells. Therefore, PC-3 cells were incubated with C-KβBA for various time periods. 
These investigations identified the downregulation of p70S6K phosphorylation as an 
event that occurred early after the treatment of PC-3 cells. In fact, the p70S6K is the 
best characterized effector downstream of mTORC1 (Ali et al. 2005) indicating that 
C-KβBA may target the PI3K/Akt/TSC/mTORC1 signaling pathway. Additionally, 
PDK1 has also been implicated in the regulation of the p70S6K phosphorylation 
(Meric-Bernstam et al. 2009). Therefore, the first step was to evaluate the relation 
between Akt (via TSC2), PDK1 and p70S6K phosphorylation. Western blot analysis 
of whole cell lysates from PC-3 cells exposed to C-KβBA and then stained for p-
PDK1 and p-Akt showed that C-KβBA had no effect on either of both kinases. In this 
context, it should be notice that p-Akt-Ser473 is regulated by mTORC2. Therefore, 
the lack of effect of C-KβBA on p-Akt-Ser473 indicates that the compound has no 
effect on mTORC2 and this constellation supports our hypothesis that C-KβBA might 
target the mTORC1 signaling pathway. 
Activation of LKB1 and AMPK inhibits p70S6K phosphorylation via TSC2 (Bai et al. 
2009; Meric-Bernstam et al. 2009). TSC2 is also a negative regulator for mTORC1. 
Yet TSC2 is regulated not only by Akt and AMPK, but also by the ERK signaling 
pathway (Bai et al. 2009). However, in PC-3 prostate cancer cells, ERK is inactive 
because we failed to detect any phosphorylation of ERK. Additionally, treatment of 
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TSC-/- MEFs cells with C-KβBA did not rescue the cell from the cytotoxicity of C-
KβBA. Thus, our data ruled out the effect of C-KβBA on the TSC2 signaling network.  
Treatment of PTEN positive PC-3 cells (which blocks the mTOR signaling pathway), 
with C-KβBA revealed that PTEN positive PC-3 cells were more resistant to C-KβBA 
compared to regular PC-3 cells, which are PTEN negative. This finding confirmed 
our hypothesis that mTOR targets the mTORC1 signaling pathway. 
Protein phosphatase 2A (PP2A) is a heterotrimeric enzyme. PP2A is one of the 
major cellular serine-threonine phosphatases and is involved in the regulation of cell 
homeostasis. Active mTOR phosphorylates p70S6K and 4EBP1 either directly or 
indirectly via inhibition of PP2A (Dufner et al. 1999). Therefore, C-KβBA could inhibit 
the phosphorylation of p70S6K by activation of PP2A. To clarify whether PP2A 
activation might be involved in the downregulation of p70S6K phosphorylation, PC-3 
cells were pretreated with C-KβBA in the presence or absence of an PP2A inhibitor 
(okadaic acid) or an unspecific phosphatase inhibitor (calyculin A). This experiment 
showed that calyculin A partially reversed the inhibitory effect of C-KβBA on p70S6K, 
while okadaic acid had no effect on p70S6K phosphorylation in PC-3 cells indicating 
that PP2A does not play a role in the C-KβBA-mediated effect on the p70S6K 
phosphorylation. This was, further confirmed in an assay of PP2A phosphatase 
activity that clearly revealed that C-KβBA has no effect on the PP2A activity. Thus, 
C-KβBA inhibited the mTORC1 signaling pathway independent of PP2A activity. This 
is in agreement with previously reported data showing that inhibition of mTOR with 
rapamycin neither induced restoration of the phosphatase activity of PP2A nor did it 
cause dissociation of α4 and Tap42 from PP2A (Nanahoshi et al. 1998). 
The eukaryotic initiation factor 4E (eIF4E) is a downstream target of mTORC1. The 
eIF4E is a mRNA 5´-cap-binding protein and is as such a central component in the 
initiation and regulation of translation in eukaryotic cells. EIF4E binding to the mRNA 
cap structure mediates the initiation of translation. Hypophosphorylation of 4EBP1 
results in its high affinity binding to eIF4E. This binding prevents eIF4E association 
with eIF4G and thereby the formation of eIF4E initiation complex. As a consequence 
the cap-dependant translation of mRNA is inhibited. mTOR phosphorylates 4EBP1, 
DISCUSSION                                                                                                                             
 
 
83 
 
which leads to the dissociation of eIF4E and the subsequent initiation of translation 
(Hay et al. 2004). It is interesting to note that activation of eIF4E is significantly 
elevated with progression of human and experimental prostate cancer, and 
significantly correlates with a diminished patient survival. By contrast, experimental 
downregulation of the eIF4E expression in prostate cancer cells elicits apoptosis in a 
cell cycle phase-independent manner (Graff et al. 2009) suggesting an essential role 
of the mTOR-regulated elF4E for the fate of prostate cancer patients. 
The relation between the phosphorylation of eIF4E and protein translation is 
controversial. It has been reported that phosphorylation of eIF4E either enhanced 
(Waskiewicz et al. 1999), or inhibited (Knauf et al. 2001), or had no effect (Morley et 
al. 2002) on protein translation. Biophysical studies indicated that phosphorylation of 
eIE4E decreases its cap-binding affinity, thereby increasing the rate of eIF4E-
m7GTP cap complex dissociation (Scheper et al. 2002). The seemingly contradictory 
findings concerning the relation between phosphorylation of eIF4E and the protein 
translation might possibly depend on the cell type and the experimental condition 
used. This controversial situation indicates that phosphorylated eIF4E may not 
necessarily be a part of the eIF4E complex required for general protein translation. 
However, it has been clearly shown that inhibition of mTOR by rapamycin or similar 
inhibitor compounds in vitro and vivo increase the phosphorylation status of eIF4E 
(Tee et al. 2000; Sun et al. 2005; Wang et al. 2007; Chen et al. 2009; Zhu et al. 
2009). Combination of rapamycin and inhibitors against MnK, ERK, p38 MAPK or 
PI3K revealed that upregulation of the eIF4E phosphorylation depends on PI3K 
signaling but is independent on the MnK signaling pathway (Sun et al. 2005). Knock 
down of MnK1 expression decreased the basal level of p-eIF4E but could not 
prevent its phosphorylation increased by rapamycin. Knockdown of mTOR (mTOR 
siRNA) or raptor (raptor siRNA), but not of rictor (rictor siRNA), hinder the 
phosphorylation of eIF4E by rapamycin (Wang et al. 2007). This indicates that the 
rapamycin-induced eIF4E phosphorylation depends on the presence of mTOR. Here 
we show that C-KβBA upregulated the eIF4E phosphorylation in PC-3 cells and 
concomitantly downregulated the eIF4E expression. 
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To shed light on the role of eIF4E hyperphosphorylation and the translation process, 
we monitored the status of the cyclin D1 expression. Cyclin D1 is a key regulator of 
the G1 phase of the cell cycle, and drives cells through the G1/S phase transition 
(Stacey 2003). Cyclin D1 mRNA translation is complex, involving both cap-
dependent and cap-independent mechanisms, and p70S6K has a central role in the 
regulation of the cyclin D1 expression (Koziczak et al. 2004). Cyclin D1 is considered 
the prime downstream target protein of eIF4E-mediated protein translation. 
Expression of eIF4E significantly correlates with the increase of cyclin D1 protein 
expression. eIF4E enhances the nuclear export of cyclin D1 mRNA (Mamane et al. 
2004; Culjkovic et al. 2005). Activation of mTOR phosphorylates p70S6K and leads 
to the recruitment of the 40S ribosomal subunit into translating polysomes, which 
enhances the translation of mRNA with 5´ terminal oligopolypyrimidine (5´-TOP) 
(Jiang et al. 2008). PC-3 cells treated with C-KβBA exhibited a clear downregulation 
of the cyclin D1 expression. This implies that C-KβBA induces inhibition of the 
translation machinery by induction of eIF4E hyperphosphorylation as well as 
downregulation of the eIF4E protein expression. 
The growth of an organ or a whole organism is mediated by increases in both cell 
size and cell number through the coordinated action of cell growth and cell cycle 
progression. Apoptosis is the physiological process by which the body removes 
unwanted cells, reforms and maintains the tissues and the organs. The disturbance 
between these two processes is the main reason for many diseases including 
cancer. This disturbance might be due to mutation of certain genes (e.g. PTEN) or 
activation of distinct signaling cascades (e.g. the mTOR signaling pathway). Under 
these conditions, the cells undergo continuous cell proliferation and growth, in the 
sense that they ‘forget’ how to die. Targeting the cell cycle at this point seems to be 
a prime opportunity to stop proliferation and growth of a tumor.  
mTOR is widely known as a governor of cell cycle progression and proliferation 
(Peponi et al. 2006). It has been previously shown that the cell cycle arrest induced 
by rapamycin occurs via p70S6K. Consistently, expression of active p70S6K 
reversed the rapamycin-induced G1 cell cycle arrest (Gao et al. 2004). Similarly, C-
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KβBA induced cell cycle arrest in the G1 phase providing further evidence that C-
KβBA inhibits the mTORC1/ p70S6K signaling pathway. 
Taken together, C-KβBA inhibits cell proliferation and induces apoptosis in vitro and 
vivo even at low concentrations and after a single, rather short exposure. C-KβBA 
elicits cell cycle arrest at G1 with inhibition of the protein translation machinery that is 
associated with the downregulation of cyclin D1. These effects of C-KβBA are 
triggered by its inhibition of the mTOR signaling pathway that occurs independent 
from the upstream kinases Akt and PDK1, and independent from the negative 
regulators of the mTOR signaling, TSC2 and PP2A. 
In conclusion, the capability of C-KβBA to inhibit the mTOR signaling pathway 
renders it an interesting lead compound for the development of novel 
pharmacotherapeutic approaches for the treatment of various diseases including 
cancer.
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5. Summary 
The apoptotic mode of cell death (programmed cell death) is an active and defined 
process that plays an important role in the development of multicellular organisms 
and in the regulation and maintenance of cell populations in tissues under 
physiologic and pathologic conditions. Since dysregulation of apoptosis is associated 
with the progress of many diseases, induction of apoptosis is an interesting 
pharmacological target for the therapy of many diseases. Our study shows that the 
novel semisynthetic pentacyclic triterpenoid C-KβBA has a profound antiproliferative 
effect on different tumor cell lines and that it induces apoptosis of tumor cells in vitro 
and vivo. 
Previous studies have shown that the mammalian target of rapamycin (mTOR) is a 
key regulator for many cells activities, and that the perturbation of this signaling 
pathway is implicated in many diseases and metabolic disorders. Accordingly, 
targeting the mTOR signaling pathway seems to be a promising therapeutic 
approach for the treatment of various diseases and metabolic disorders.  
We have shown in our study that C-KβBA downregulates the mTOR signaling 
pathway in vitro and vivo, which leads to the induction of cell cycle arrest in the G0 
cell cycle phase as well as downregulation of the protein translation machinery. 
Together, the presented data strongly suggest that C-KβBA could serve as a lead 
compound for the development of novel treatment modalities for diseases and 
disorders associated with defects in the apoptosis machinery, or the mTOR signaling 
pathway, or both. 
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6. Zusammenfassung 
Der programmierte Zelltod ist ein aktiver und wohldefinierter Prozess. Unter 
physiologischen und pathophysiologischen Bedingungen spielt er eine 
entscheidende Rolle sowohl bei der Entwicklung mehrzelliger Organismen als auch 
bei der Regulation und Erhaltung verschiedener Zellpopulationen. Da das 
Fortschreiten vieler Erkrankungen mit einer Fehlregulation der Apoptose einhergeht, 
wird der Apoptoseprozess heute als ein wichtiger Angriffspunkt pharmakologischer 
Therapieansätze betrachtet. Unsere Studien zeigen, dass das neuartige 
semisynthethische Triterpenoid C-KβBA einen starken antiproliferativen Effekt auf 
verschiedene Tumorzelllinien besitzt und dass es sowohl in vitro als auch in vivo zur 
Induktion von Apoptose führt. 
In verschiedenen Studien konnte bereits früher gezeigt werden, dass dem 
„mammalian target of rapamycin“ (mTOR) eine Schlüsselrolle in der Regulation 
verschiedener Zellaktivitäten zukommt. Eine Störung dieses Signalweges kann mit 
vielerlei Erkrankungen und metabolischen Fehlfunktionen in Verbindung gebracht 
werden. Somit könnte der mTOR-Signalweg das Ziel eines vielversprechenden 
Therapieansatzes für die Behandlung diverser Erkrankungen und metabolischer 
Störungen sein. 
In unseren Studien konnten wir zeigen, dass C-KβBA den mTOR Signalweg sowohl 
in vitro als auch in vivo hemmt. Diese Inhibition führt zu einem Zellzyklusarrests in 
der G0-Phase sowie zu einer Hemmung der Proteintranslation.  
Zusammenfassend implizieren die hier präsentierten Daten, dass C-KβBA als eine 
prototypische Modellsubstanz für die Entwicklung neuer Therapieansätze für 
Erkrankungen mit aberranten Funktionen entweder der apoptotischen Maschinerie 
oder des mTOR-Signaltransduktionsweges dienen könnte.  
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